Protected when completed

Date Submitted: 2025-02-07 17:12:13
Confirmation Number: 1907594
Template: Full CV

Dr. Antoine Desilets

Correspondence language: French
Sex: Male
Date of Birth: 9/25
Canadian Residency Status: Canadian Citizen
Country of Citizenship: Canada

Contact Information

The primary information is denoted by (*)

Address

Home (*)

6636 rue Chambord
Montréal Quebec H2G3B9
Canada

Telephone

Mobile (*) 1-514-566-5788

Email

Work (*) antoine.desilets.med@ssss.gouv.qc.ca

Website

https://www.chumontreal.qc.ca/crchum/chercheurs/antoine-desilets

Protected when completed

Dr. Antoine Desilets

Language Skills

Language	Read	Write	Speak	Understand	Peer Review
English	Yes	Yes	Yes	Yes	Yes
French	Yes	Yes	Yes	Yes	Yes

Degrees

2020/9 - 2024/6

Master's Thesis, Biomedical Sciences, Experimental Medicine, Université de Montréal
Degree Status: Completed
Thesis Title: Inhibiteurs du point de contrôle immunitaire en carcinome pulmonaire : approches immunomodulatrices Immune Checkpoint Inhibitors in Lung Carcinoma: Immunomodulatory Approaches

Supervisors: Bertrand Routy, 2020/9 - 2023/12

Research Disciplines: Oncology, Immunology, Microbiology, Genetics

Areas of Research: Lung Cancer, Immunotherapy, Microorganisms, Cancer Genetics

Fields of Application: Pathogenesis and Treatment of Diseases

2021/7 - 2022/6

Diploma, Postdoctoral Studies, Hematology, Université de Montréal
Degree Status: Completed

Supervisors: Silvy Lachance

2019/7 - 2021/10

Diploma, Postdoctoral Studies, Medical Oncology, Université de Montréal
Degree Status: Completed

Supervisors: Jean-Luc Dionne

2016/7 - 2019/6

Diploma, Postdoctoral Studies, Internal Medicine, Université de Montréal
Degree Status: Completed

Supervisors: Claude Poirier

2011/8 - 2016/5

Doctorate, MDCM, McGill University
Degree Status: Completed
Transferred to PhD without completing Masters?: Yes

Supervisors: David Eidelman

Credentials

2024/6

MSc, Université de Montréal
Master's in Biomedical Sciences, Experimental Medicine option, completed under the supervision of Dr. Bertrand Routy in the Oncology-Microbiome Laboratory at CRCHUM. Thesis title: Immune Checkpoint Inhibitors in NSCLC: Immunomodulatory Approaches.

Research Disciplines: Oncology

Areas of Research: Immunotherapy, Lung Cancer, Microorganisms, Cancer Genetics

Fields of Application: Pathogenesis and Treatment of Diseases

2022/11

Hématologie / Hematology, Royal College of Physicians and Surgeons of Canada
Certificat de surspécialité Subspecialty certificate

2021/10

Oncologie médicale / Medical oncology, Royal College of Physicians and Surgeons of Canada
Certificat de surspécialité Subspecialty certificate

2020/6

Médecine interne / Internal Medicine, Royal College of Physicians and Surgeons of Canada
Certificat de spécialiste Specialist certificate

2016/5

MD, McGill University
Doctor of Medicine and Master of Surgery (MDCM)

Recognitions

2024/6 - 2024/6

ASCO Annual Meeting 2024 Merit Award - 1,000 (United States dollar)
American Society of Clinical Oncology (ASCO)
Prize / Award
Merit Award recognizing oncology research fellows whose research is addressed in high-quality abstracts submitted to the ASCO Annual Meeting and recognized for their scientific merit. Project: Germline and somatic MUTYH mutations: Clinicopathologic and mutational analysis in a pan-cancer cohort.

Research Disciplines: Oncology

Areas of Research: Cancer Genetics

Fields of Application: Biomedical Aspects of Human Health

2024/4 - 2024/4

AACR Scholar-in-Training Award 2024 - 1,400 (United States dollar)
American Association for Cancer Research
Prize / Award
American Association for Cancer Research (AACR) 2024 Scholar-in-Training Award granted for outstanding research contributions in the fields of basic, clinical, and translational cancer research. Oral presentation: PTCH1 loss-of-function alterations: Mutational landscape and therapeutic outcomes to hedgehog pathway inhibitors in non-canonical histologies.

Research Disciplines: Oncology

Areas of Research: Cancer Genetics

Fields of Application: Pathogenesis and Treatment of Diseases

2024/4 - 2024/4 Texas Lung Cancer Conference Research Competition 2024 - First Position - 0 (United States dollar)
Texas Lung Cancer Conference
Prize / Award
Poster research competition at the Texas Lung Cancer Conference 2024. Project: Selpercatinib resistance: Genomic determinants of progression in patients with RET fusion-positive non-small cell lung cancer.

Research Disciplines: Oncology

Areas of Research: Cancer Genetics

Fields of Application: Pathogenesis and Treatment of Diseases

2023/7 - 2023/7 AACR-AHNS Scholar-in-Training Award 2023 - 1,000 (United States dollar)
American Association for Cancer Research
Prize / Award
American Association for Cancer Research (AACR) and American Head and Neck Society (AHNS) 2023 Scholar-in-Training Award granted for exceptional research contributions to the fields of basic, clinical, and translational research. Presentation: Durvalumab in combination with radioactive iodine in recurrent/metastatic thyroid cancers: update on clinical and correlative analyses.

Research Disciplines: Oncology

Areas of Research: Head and Neck Cancer

Fields of Application: Biomedical Aspects of Human Health

2022/7 - 2024/10 Bourse de fellowship de la Fondation du CHUM / Fondation du CHUM Fellowship Scholarship - 100,000 (Canadian dollar)
Centre hospitalier de l'Université de Montréal
Distinction
Competitive fellowship funding scholarship awarded by CHUM to programs demonstrating significant potential for positive impact on patients and the institution

Research Disciplines: Oncology

Areas of Research: Cancer Genetics

Fields of Application: Pathogenesis and Treatment of Diseases

2022/7 - 2022/7 Bourse de la Fondation R. Samuel McLaughlin / R. Samuel McLaughlin Foundation Scholarship - 25,000 (Canadian dollar)
Université de Montréal
Distinction
Scholarship awarded by the Faculty of Medicine at the Université de Montréal to support candidates who demonstrate excellence in their background (academic record, research activities, publications) and are pursuing research work and additional training outside of Quebec.

Research Disciplines: Oncology

Areas of Research: Cancer Genetics

Fields of Application: Pathogenesis and Treatment of Diseases

2022/7 - 2022/7 Prix d’excellence du résident/Resident Excellence Award - 1,000 (Canadian dollar)
Centre hospitalier de l'Université de Montréal
Distinction
Awarded by the CHUM Department of Medicine to the resident who has demonstrated exceptional distinction in academic achievements during their training

2021/5 - 2021/5	Compétition de recherche de l'AMHOQ 2021 - Première position / AMHOQ 2021 Research Competition - First Position - 1,000 (Canadian dollar) Association des médecins hématologues et oncologues du Québec (AMHOQ) Prize / Award Research Disciplines: Oncology Areas of Research: Lung Cancer Fields of Application: Pathogenesis and Treatment of Diseases
2021/4 - 2021/4	Bourse d'excellence prédémarrage Q-CROC-Oncopole / Q-CROC-Oncopole Pre-Startup Excellence Award - 0 (Canadian dollar) Q-CROC-Oncopole Distinction Q-CROC - Clinical Oncology Research. Description: Award given to a physician-researcher for the initiation of a promising clinical trial, including 6 hours of guidance and training with a Health Canada Good Clinical Practices expert consultant. Project: CRYO-VATE: Pilot study of lung cancer cryo-activation in combination with immunotherapy in advanced non-small cell lung cancer. Research Disciplines: Oncology Areas of Research: Lung Cancer Fields of Application: Pathogenesis and Treatment of Diseases
2020/5 - 2020/5	Compétition de recherche de l'AMHOQ 2020 - Première position / AMHOQ 2020 Research Competition - First Position - 1,000 (Canadian dollar) Association des médecins hématologues et oncologues du Québec (AMHOQ) Prize / Award Research Disciplines: Oncology Areas of Research: Head and Neck Cancer Fields of Application: Pathogenesis and Treatment of Diseases
2019/5 - 2019/5	Compétition de recherche de l'AMHOQ 2019 - Deuxième position / AMHOQ 2019 Research Competition - Second Position - 500 (Canadian dollar) Association des médecins hématologues et oncologues du Québec (AMHOQ) Prize / Award Research Disciplines: Oncology Areas of Research: Cancer of the Digestive System Fields of Application: Pathogenesis and Treatment of Diseases
2015/1 - 2015/1	T.F. Rose Scholarship / Bourse T.F. Rose - 7,500 (Canadian dollar) McGill University Distinction Awarded by McGill Faculty of Medicine on the basis of academic success

User Profile

Researcher Status: Researcher
Research Career Start Date: 2025/01/06
Engaged in Clinical Research?: Yes

Key Theory / Methodology: Investigator-initiated clinical trials Genetic biomarkers of response

Research Interests: Precision oncology (tumor-agnostic treatments based on next-generation sequencing) Non-small cell lung cancer (NSCLC) Head and neck squamous cell cancer (HNSCC)

Research Experience Summary: I am a physician-scientist specializing in precision oncology. My research integrates genetic biomarkers of response through tissue next-generation sequencing (NGS) and liquid biopsies. I completed my medical training at McGill University and a Master's degree at Université de Montréal under Dr. Bertrand Routy. My thesis focused on the impact of the microbiome on response to immune checkpoint inhibitors in non-small cell lung cancer, as characterized by metagenomics, thus building my expertise in statistics, bioinformatics, and multiomic models in oncology. I later completed a 2-year research fellowship at Memorial Sloan Kettering Cancer Center under Dr. Alexander Drilon and Dr. Alan Ho. My work in cancer genomics and targeted therapies, through the development of multiple investigator-initiated trials, led to a number of publications and recognition with awards from ASCO and AACR. I am committed to advancing cancer treatments through personalized, biomarker-driven approaches.

Research Specialization Keywords: Precision Oncology, Next-Generation Sequencing, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Cancer, Melanoma

Research Centres: Centre de recherche du CHUM

Technological Applications: Antineoplasics, Monoclonal antibodies, Monitoring and diagnostic equipment

Disciplines Trained In: Oncology

Research Disciplines: Oncology, Molecular Biology, Pharmacology

Areas of Research: Cancer Genetics, Oncogenes, Lung Cancer, Head and Neck Cancer, Skin Cancer

Fields of Application: Pathogenesis and Treatment of Diseases

Countries: Canada

Employment

2024/10	Professeur adjoint de clinique Centre hospitalier de l'Université de Montréal Full-time, Adjunct, Assistant Professor Tenure Status: Tenure, 2024/10 - Professeur adjoint de clinique au sein de la Faculté de médecine de l'Université de Montréal et hémato-oncologue au Centre hospitalier de l'Université de Montréal (CHUM) Research Disciplines: Oncology, Genetics, Molecular Biology Areas of Research: Cancer Genetics, Immunotherapy, Chemotherapy, Lung Cancer, Head and Neck Cancer, Skin Cancer Fields of Application: Pathogenesis and Treatment of Diseases

Affiliations

The primary affiliation is denoted by (*)

(*) 2024/10	Principal Investigator, Centre de recherche du CHUM, CHUM Research Centre (CRCHUM) Investigateur principal au sein de l'Axe Cancer du CRCHUM impliqué dans le recrutement de patients éligibles pour études de phase I et II basées sur la présence d'un biomarqueur génétique (Unité d'innovations thérapeutiques; UIT) et études de phase III en cancer de la tête et du cou, pulmonaire ou mélanome (Unité de recherche clinique en oncologie et hématologie; URCOH). Principal Investigator in the Cancer Axis of CRCHUM involved in recruiting eligible patients for phase I and II studies based on the presence of a genetic biomarker (Therapeutic Innovations Unit; UIT) and phase III studies in head and neck cancer, lung cancer, or melanoma (Oncology and Hematology Clinical Research Unit; URCOH).

2022/7 - 2024/12 Post-doctoral Research Fellow, Memorial Sloan-Kettering Cancer Center
Stage de perfectionnement (fellowship) de recherche d'une durée de 2 ans axé sur la caractérisation de biomarqueurs moléculaires de réponse par séquençage génétique de nouvelle génération (NGS) en oncologie et la conception d'études cliniques initiées par l'investigateur. Formation sous la supervision des Drs Alexander Drilon et Alan Ho. 2-year research fellowship focused on the characterization of molecular biomarkers of response through next-generation sequencing (NGS) in oncology and the design of investigator-initiated clinical trials. Training under the supervision of Drs Alexander Drilon and Alan Ho.

2020/9 - 2023/12 Master student, Université de Montréal
Étudiant à la maîtrise en sciences biomédicales sous la supervision du Dr Bertrand Routy au sein du Laboratoire d'oncologie-microbiome du CRCHUM. Responsabilités incluant l'organisation des banques de données, expertise en statistiques et bioinformatique, rédaction d'articles scientifiques, approches multiomiques pour la pronostication du cancer du poumon non à petites cellules, conception de méta-analyses, méta-génomique du microbiome et techniques de laboratoire. Master's Student in biomedical sciences under the supervision of Dr. Bertrand Routy in the Oncology-Microbiome Laboratory at CRCHUM. Responsibilities included data bank organization, expertise in statistics and bioinformatics, scientific article writing, multiomic approaches for the prognostication of non-small cell lung cancer, meta-analysis design, microbiome metagenomics, and laboratory techniques.

Research Funding History

Completed [n=2]

2023/1 - 2023/12
Principal Applicant

Bourse de la Fondation du CHUM 2022, Fellowship
Clinical Research Project?: Yes

Research Uptake Stakeholders: Patients

Research Settings: United States of America (Urban)

Funding Sources:

2023/1 - 2023/12 Fondation du Centre Hospitalier de l'Université de Montréal (CHUM)
Bourses de fellowship 2022
Total Funding - 25,000 (Canadian dollar)
Portion of Funding Received - 25,000 (Canadian dollar)
Funding Renewable?: No
Funding Competitive?: Yes

Funding by Year:

2023/1 - 2023/12 Total Funding - 25,000 (Canadian dollar)
Portion of Funding Received - 0 (Canadian dollar)
Time Commitment: 100

Research Disciplines: Oncology

Areas of Research: Head and Neck Cancer, Lung Cancer

Fields of Application: Pathogenesis and Treatment of Diseases

2022/7 - 2022/12
Principal Applicant

Bourse de la Fondation Samuel R. McLaughlin 2021-2022, Fellowship
Clinical Research Project?: Yes

Research Uptake Stakeholders: Patients

Research Settings: United States of America (Urban)

Funding Sources:

2022/7 - 2022/7
University of Montreal
Fondation Samuel R. McLaughlin
Total Funding - 25,000 (Canadian dollar)
Portion of Funding Received - 25,000 (Canadian dollar)
Funding Renewable?: No
Funding Competitive?: Yes

Funding by Year:

2022/7 - 2022/12
Total Funding - 25,000 (Canadian dollar)
Portion of Funding Received - 25,000 (Canadian dollar)
Time Commitment: 80

Research Disciplines: Oncology

Areas of Research: Head and Neck Cancer, Lung Cancer

Fields of Application: Pathogenesis and Treatment of Diseases

Journal Review Activities

2024/10 - 2024/10
Reviewer,Cancer Research Communications,American Association for Cancer Research (AACR)
Number of Works Reviewed / Refereed: 1

2024/9 - 2024/9
Reviewer,Clinical Cancer Research,American Association for Cancer Research (AACR)
Number of Works Reviewed / Refereed: 1

2024/7 - 2024/7
Reviewer,Expert Opinion On Drug Safety,Taylor & Francis
Number of Works Reviewed / Refereed: 1

International Collaboration Activities

2024/4
Collaborateur de recherche / research collaborator, United States of America
Collaboration entre le Mount Sinai Hospital (New York, États-Unis) et le CRCHUM dans le cadre d'études cliniques initiées par les investigateurs, avec une fenêtre d'opportunité, évaluant les corrélats immunitaires et moléculaires chez les patients recevant une immunothérapie néoadjuvante. Cette collaboration inclut des accords de transfert de matériel vers le CHUM pour des analyses sur le microbiome. Collaboration between Mount Sinai Hospital (New York, USA) and the CRCHUM on window-of-opportunity, investigator-initiated clinical trials evaluating immune and molecular correlates in patients receiving neoadjuvant immunotherapy. This collaboration includes material transfer agreements to the CHUM for microbiome analyses.

2022/7
Collaborateur et fellow de recherche / research fellow and collaborator, United States of America
Collaboration entre le Memorial Sloan Kettering Cancer Center (New York, États-Unis) et le CRCHUM pour différentes études rétrospectives portant sur le traitement systémique du cancer du poumon et du mélanome Collaboration between Memorial Sloan Kettering Cancer Center (New York, USA) and the CRCHUM on various retrospective studies focused on systemic treatment of lung cancer and melanoma

2020/7 Collaborateur de recherche / research collaborator, France
Collaboration entre l'Institut Gustave Roussy (Paris, France) et le Centre de microbiome du CHUM pour diverses analyses du microbiome chez les patients atteints de cancer et traités par immunothérapie. Collaboration between the Institut Gustave Roussy (Paris, France) and the CHUM Microbiome Center on various microbiome analyses in cancer patients treated with immunotherapy. Publications (PMID): 35115705, 34400407, 39014160

Committee Memberships

2024/10 Committee Member, Pogramme de médecine personnalisée en oncologie porté par le Fonds Guy Lafleur / Personalized Medicine in Oncology Program supported by the Guy Lafleur Fund, Centre hospitalier de l'Université de Montréal
Consultant en oncologie de précision et en recherche clinique dans le cadre du programme, pour des discussions sur les orientations stratégiques et le développement du séquençage génétique de nouvelle génération (NGS), ainsi que pour la création d'une interface numérique de données génomiques au CRCHUM afin de soutenir la recherche translationnelle Precision oncology and clinical research consultant within the program, involved in strategic discussions and the development of next-generation sequencing (NGS) as well as the creation of a digital genomic data interface at CRCHUM to support translational research

2024/10 Committee Member, Service de diagnostic moléculaire du CHUM / Molecular Diagnostic Service of CHUM, Centre hospitalier de l'Université de Montréal
Contrôle de qualité et mise en place d'une banque de données institutionnelle au niveau du séquençage génétique de nouvelle génération (NGS) pour l'ensemble des spécimens tumoraux analysés au CHUM. Élaboration et mise à jour du rapport de recommandations cliniques, incluant les études cliniques disponibles au CRCHUM, en partenariat avec l'équipe de pathologie moléculaire du CHUM. Développement stratégique des technologies de NGS non invasives par biopsie liquide au CHUM et CRCHUM. Quality control and establishment of an institutional database for next-generation sequencing (NGS) of all tumor specimens analyzed at CHUM. Development and regular updates of clinical recommendation reports, including available clinical trials at CRCHUM, in partnership with the molecular pathology team at CHUM. Oversight of the strategic development of non-invasive NGS technologies through liquid biopsy at CHUM and CRCHUM.

Presentations

1. (2024). Hedgehog pathway inhibitors in patients with non-small cell lung cancer. IASLC Targeted Therapies of Lung Cancer Meeting 2024, Santa Monica, United States of America
Main Audience: Researcher
Invited?: Yes, Keynote?: No, Competitive?: Yes

2. (2024). PTCH1 mutational landscape and therapeutic outcomes on hedgehog pathway inhibitors in a tumor-agnostic cohort. OncLive National Fellows Forum – Tumor Agnostic 2024, Miami, United States of America
Main Audience: Researcher
Invited?: Yes, Keynote?: No, Competitive?: Yes

3. Matteo Repetto. (2024). Clinicopathologic and allele-specific analysis of germline and somatic MUTYH alterations in a pan-cancer cohort. CGA-IGC 2024, Philadelphia, United States of America
   Main Audience: Researcher
   Invited?: Yes, Keynote?: No, Competitive?: Yes
4. (2024). Selpercatinib in RET-fusion positive non-small cell lung cancer: mechanisms of primary and acquired resistance using next-generation sequencing. Texas Lung Cancer Conference 2024, Ausin, United States of America
   Main Audience: Researcher
   Invited?: Yes, Keynote?: No, Competitive?: Yes
5. (2024). PTCH1 loss-of-function alterations: Mutational landscape and therapeutic outcomes to hedgehog pathway inhibitors in non-canonical histologies. AACR - Annual Meeting 2024, San Diego, United States of America
   Main Audience: Researcher
   Invited?: Yes, Keynote?: No, Competitive?: Yes
6. (2023). Selpercatinib resistance: genomic determinants of early progression in patients with RET fusion-positive cancers. OncLive National Fellows Forum – Precision Medicine, Washington DC, United States of America
   Main Audience: Researcher
   Invited?: Yes, Keynote?: No, Competitive?: Yes
7. Jean-Nicolas Champagne. (2023). The Impact of Restrictive Measures on Optimal use of Intravenous Immunoglobulin. Canadian Society for Transfusion Medicine Conference, Montreal, Canada
   Main Audience: Researcher
   Invited?: Yes, Keynote?: No, Competitive?: Yes
8. Jean-Nicolas Champagne. (2022). Impact of blood bank auditing on optimal use of intravenous immunoglobulins in hematology at CHUM. AMHOQ – Rencontre annuelle 2022, Virtual, Canada
   Main Audience: Researcher
   Invited?: Yes, Keynote?: No, Competitive?: Yes
9. (2021). Durvalumab post chimioradiothérapie chez NSCLC – Expérience « Real World ». Réunion scientifique d'hématologie-oncologie – Hôpital Honoré-Mercier, Sainte-Hyacinthe, Canada
   Main Audience: Decision Maker
   Invited?: Yes, Keynote?: No, Competitive?: No
10. (2021). Covid-19 en hémato-oncologie – Une expérience pancanadienne. Réunion scientifique d'hématologie-oncologie – Hôpital Maisonneuve-Rosemont, Montréal, Canada
    Main Audience: Researcher
    Invited?: Yes, Keynote?: No, Competitive?: No
11. (2021). Durvalumab post chimioradiothérapie chez NSCLC – Expérience « Real World ». AMHOQ – Rencontre annuelle 2021, Virtuel, Canada
    Main Audience: Researcher
    Invited?: Yes, Keynote?: No, Competitive?: Yes
12. (2020). Infection à la Covid-19 chez patients avec cancer – Une expérience multicentrique. AMHOQ – Rencontre annuelle 2020, Virtuel, Canada
    Main Audience: Researcher
    Invited?: Yes, Keynote?: No, Competitive?: No
13. Arielle Elkrief. (2020). Efficacy of durvalumab in combination with chemoradiotherapy in stage III non-small cell lung cancer: real-world data from multicentric cohorts. Schulich School of Medicine Immuno-Oncology Symposium, London, Canada
    Main Audience: Researcher
    Invited?: Yes, Keynote?: No, Competitive?: Yes

14. (2020). Covid-19 en hémato-oncologie – Une expérience pancanadienne. Réunion scientifique d'hématologie-oncologie – CHUM, Montréal, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: No, Competitive?: No

15. Arielle Elkrief. (2020). High mortality among hospital-acquired COVID-19 infection in patients with cancer: an observational cohort study from Quebec and British Columbia. AACR – Covid Symposium, Virtual, United States of America
Main Audience: Researcher
Invited?: Yes, Keynote?: No, Competitive?: Yes

16. (2019). Dépistage DPYD chez carcinomes oropharyngés traités sous chimioradiothérapie concomitante à base de 5-FU : une étude rétrospective. AMHOQ – Rencontre annuelle 2019, Montebello, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: No, Competitive?: Yes

17. (2018). Adénocarcinome pancréatique du jeune adulte : caractéristiques et issues cliniques. Journée de la recherche du CHUM 2018, Montréal, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: No, Competitive?: Yes

18. (2018). NTRK et thérapies ciblées. Réunion scientifique d'hématologie-oncologie – CHUM, Montréal, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: No, Competitive?: No

19. (2018). Adénocarcinome pancréatique du jeune adulte : caractéristiques et issues cliniques. AMHOQ – Rencontre annuelle 2018, Québec, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: No, Competitive?: Yes

Publications

Journal Articles

1. Elkrief, A; Méndez-Salazar, E O; Maillou, J; Vanderbilt, C M; Gogia, P; Desilets, A; Messaoudene, M; Kelly, D; Ladanyi, M; Hellmann, M D; Zitvogel, L Rudin, C M; Routy, B; Derosa, L; Schoenfeld, A J. (2024). Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy. npj Precision Oncology. 8(1)
http://dx.doi.org/10.1038/s41698-024-00630-w
Co-Author, Springer Nature, United Kingdom
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 15
Contribution Percentage: 21-30

2. Champagne, J N; Desilets, A; Roy, G; Landon-Cardinal, O; Chapdelaine, H; Matte, G; Bouchard, C; Rioux-Massé, B; Lemay, A S. (2024). The impact of institutional measures on optimal use of intravenous immunoglobulin. Transfusion.
http://dx.doi.org/10.1111/trf.18031
Co-Author
Published, Wiley, United States of America
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 9
Contribution Percentage: 31-40

3. Desilets, A; Repetto, M; Drilon, A. (2024). Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer. Clinical and Translational Medicine. 14(10): e70017.
http://dx.doi.org/10.1002/ctm2.70017
First Listed Author
Published, Wiley, United States of America
Refereed?: Yes, Open Access?: Yes, Synthesis?: Yes
Number of Contributors: 3
Contribution Percentage: 91-100

4. Chen, M F; Yang, S R; Tao, J J; Desilets, A; Diamond, E L; Wilhelm, C; Rosen, E; Gong, Y; Mullaney, K; Torrisi, J; Young, R J; Somwar, R; Yu, H A; Kris, M G; Riely, G J; Arcila, M E; Ladanyi, M; Donoghue, M T A; Rosen, N; Yaeger, R; Drilon, A; Murciano-Goroff, Y R; Offin, M. (2024). Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets. Clinical Cancer Research. 30(17): 3812-3823.
http://dx.doi.org/10.1158/1078-0432.Ccr-23-3981
Co-Author
Published, American Association for Cancer Research (AACR), United States of America
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 23
Contribution Percentage: 21-30

5. Desilets A; Lucas J; Licitra L F; Xu S; Lu S; Tse A; Tang T; Dreyer K; He N; Birgerson L E; Faivre S; Soulières D. (2024). Buparlisib and paclitaxel in patients with head andneck squamous cell cancer: immunogenomic biomarkers of efficacy from theBERIL-1 study. Targeted Oncology.
First Listed Author
Revision Requested,
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 12
Contribution Percentage: 81-90

6. Desilets A; Repetto M; Yang S R; Drilon A. (2024). Treatment of non–small cell lung cancerwith ROS1 fusions. Cancer.
First Listed Author
Accepted, Wiley, United States of America
Refereed?: Yes, Open Access?: Yes, Synthesis?: Yes
Number of Contributors: 4
Contribution Percentage: 91-100

7. Desilets, A; Pfister, D G; Stein, S; Wong, W; Sherman, E J; Fetten, J; Hung, T K W; Kriplani, A; Dunn, L A; Ho, A L; Michel, L S. (2024). A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer. Oral Oncology. 154
http://dx.doi.org/10.1016/j.oraloncology.2024.106861
First Listed Author
Published, Elsevier, Netherlands
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 11
Contribution Percentage: 81-90

8. Desilets, A; Pinheiro, G; Belkaid, W; Salko, O; Malo, J; Zarour, E; Jouquan, A; Thibaudeau, A-J; Nolin, M-A; Stagg, J; Florescu, M; Tehfe, M; Blais, N; Tabchi, S; Chalaoui, J; Stephenson, P; Elkrief, A; Trinh, V Q-H; Routy, B; Liberman, M. (2024). CRYO-VATE: Pilot study of lung cancer cryo-activation in combination with immunotherapy in advanced non-small cell lung cancer. Journal of Thoracic Oncology CRR. http://dx.doi.org/10.1016/j.jtocrr.2024.100737
First Listed Author
In Press, Elsevier, Netherlands
Refereed?: Yes, Open Access?: Yes, Synthesis?: Yes
Number of Contributors: 20
Contribution Percentage: 81-90

9. Desilets, A; Vos, J L; Katabi, N; Kuo, F; Nadeem, Z. Linxweiler, M; Ostrovnaya, I; Baxi, S; Dunn, L A; Sherman, E J; Pfister, D G; Morris, L G T; Ho, A L. (2024). Phase 2 trial of regorafenib in recurrent or metastatic adenoid cystic carcinoma. Clinical Cancer Research. 154 http://dx.doi.org/10.1158/1078-0432.Ccr-24-1064
First Listed Author
Published, American Association for Cancer Research (AACR), United States of America
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 13
Contribution Percentage: 81-90

10. Desilets, A; Repetto, M; Yang, S R; Sherman, E J; Drilon, A. (2023). RET-Altered Cancers-A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity. Cancers. 15(16) http://dx.doi.org/10.3390/cancers15164146
First Listed Author
Published, MDPI, Switzerland
Refereed?: Yes, Open Access?: Yes, Synthesis?: Yes
Number of Contributors: 5
Contribution Percentage: 91-100

11. Hes, C; Desilets, A; Tonneau, M; El Ouarzadi, O; De Figueiredo Sousa, M; Bahig, H; Filion, É; Nguyen-Tan, P F; Christopoulos, A; Benlaïfaoui, M; Derosa, L; Alves Costa Silva, C; Ponce, M; Malo, J; Belkaid, W; Charpentier, D; Aubin, F; Hamilou, Z; Jamal, R; Messaoudene, M; Soulières, D; Routy, B. (2023). Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma. Oral Oncology. 148 http://dx.doi.org/10.1016/j.oraloncology.2023.106623
First Listed Author
Published, Elsevier, Netherlands
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 22
Contribution Percentage: 81-90

12. Desilets, A; Ho, A L. (2023). Nivolumab in salivary gland cancers: confronting the challenges of unlocking the therapeutic benefits of immunotherapy for rare diseases. BMJ Oncology. 2(1) http://dx.doi.org/10.1136/bmjonc-2023-000214
First Listed Author
Published, BMJ Publishing Group Ltd., United Kingdom
Refereed?: Yes, Open Access?: Yes, Synthesis?: Yes
Number of Contributors: 2
Contribution Percentage: 91-100

13. Desilets, A; Elkrief, A. (2023). Following your gut: the emerging role of the gut microbiota in predicting and treating immune-related adverse events. Current Opinion in Oncology. 35(4): 248-253.
http://dx.doi.org/10.1097/cco.0000000000000957
First Listed Author
Published, Wolters Kluwer, Netherlands
Refereed?: Yes, Open Access?: Yes, Synthesis?: Yes
Number of Contributors: 2
Contribution Percentage: 91-100

14. Desilets, A; Soulières, D. (2022). PI3K Inhibition for Squamous Cell Head and Neck Carcinoma. The Cancer Journal. 28(5): 369-376.
http://dx.doi.org/10.1097/PPO.0000000000000618
First Listed Author
Published, Wolters Kluwer, Netherlands
Refereed?: No, Open Access?: Yes, Synthesis?: Yes
Number of Contributors: 2
Contribution Percentage: 91-100

15. Desilets, A; Ho, AL. (2022). Targeting HRAS in Head and Neck Cancer: Lessons From the Past and Future Promise. The Cancer Journal. 28(5): 363-368.
http://dx.doi.org/10.1097/PPO.0000000000000616
First Listed Author
Published, Wolters Kluwer, Netherlands
Refereed?: No, Open Access?: Yes, Synthesis?: Yes
Number of Contributors: 2
Contribution Percentage: 91-100

16. Derosa, L; Routy, B; Thomas, AM; Iebba, V; Zalcman, G; Friard, S; Mazieres, J; Audigier-Valette, C; Moro-Sibilot, D; Goldwasser, F; Silva, CAC; Terrisse, S; Bonvalet, M; Scherpereel, A; Pegliasco, H; Richard, C; Ghiringhelli, F; Elkrief, A; Desilets, A; Blanc-Durand, F; Cumbo, F; Blanco, A; Boidot, R; Chevrier, S; Daillère, R; Kroemer, G; Alla, L; Pons, N; Le Chatelier, E; Galleron, N; Roume, H; Dubuisson, A; Bouchard, N; Messaoudene, M; Drubay, D; Deutsch, E; Barlesi, F; Planchard, D; Segata, N; Martinez, S; Zitvogel, L; Soria, JC; Besse, B. (2022). Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nature Medicine. 28(2): 315-324.
http://dx.doi.org/10.1038/s41591-021-01655-5
Co-Author
Published, Springer Nature, United Kingdom
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 43
Contribution Percentage: 21-30

17. Desilets, A; McCarvill, W; Aubin, F; Bahig, H; Ballivy, O; Charpentier, D; Filion, E; Jamal, R; Lambert, L; Nguyen-Tan, PF; Vadnais, C; Weng, X; Soulières, D. (2022). Upfront DPYD Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress. Current Oncology. 29(2): 497-509.
http://dx.doi.org/10.3390/curroncol29020045
First Listed Author
Published, MDPI, Switzerland
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 13
Contribution Percentage: 91-100

18. Desilets, A; Elkrief, A; Routy, B. (2021). The Link Between the Gut Microbiome and Response to Immune Checkpoint Inhibitors in Renal Cell Carcinoma. European Urology. 79(1): 1-2.
http://dx.doi.org/10.1016/j.eururo.2020.09.001
First Listed Author
Published, Elsevier, Netherlands
Refereed?: Yes, Open Access?: Yes, Synthesis?: Yes
Number of Contributors: 3
Contribution Percentage: 91-100

19. Derosa, L; Routy, B; Desilets, A; Daillère, R; Terrisse, S; Kroemer, G; Zitvogel, L. (2021). Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?. Cancer Discovery. 11(10): 2396-2412.
http://dx.doi.org/10.1158/2159-8290.CD-21-0236
Co-Author
Published, American Association for Cancer Research (AACR), United States of America
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 7
Contribution Percentage: 51-60

20. Cvetkovic, L; Régis, C; Richard, C; Derosa, L; Leblond, A; Malo, J; Messaoudene, M; Desilets, A; Belkaid, W; Elkrief, A; Routy, B; Juneau, D. (2021). Physiologic colonic uptake of (18)F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. European Journal of Nuclear Medicine and Molecular Imaging. 48(5): 1550-1559.
http://dx.doi.org/10.1007/s00259-020-05081-6
Co-Author
Published, Springer Nature, United Kingdom
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 12
Contribution Percentage: 21-30

21. Desilets, A; Blanc-Durand, F; Lau, S; Hakozaki, T; Kitadai, R; Malo, J; Belkaid, W; Richard, C; Messaoudene, M; Cvetkovic, L; Kazandjian, S; Tehfe, M; Florescu, M; Jao, K; Daaboul, N; Owen, S; Shieh, B; Agulnik, J; Cohen, V; Charbonneau, C; Marcoux, N; Blais, N; Leighl, NB; Bradbury, PA; Liu, G; Shepherd, FA; Bahig, H; Routy, B; Sacher, A; Elkrief, A. (2021). Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study. European Journal of Cancer. 142: 83-91.
http://dx.doi.org/10.1016/j.ejca.2020.10.008
First Listed Author
Published, Elsevier, Netherlands
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 30
Contribution Percentage: 81-90

22. Deschênes-Simard, X; Richard, C; Galland, L; Blais, F; Desilets, A; Malo, J; Cvetkovic, L; Belkaid, W; Elkrief, A; Gagné, A; Hamel, MA; Orain, M; Joubert, P; Ghiringhelli, F; Routy, B; Blais, N. (2021). Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study. Thrombosis Research. 205: 29-39.
http://dx.doi.org/10.1016/j.thromres.2021.06.018
Co-Author
Published, Elsevier, Netherlands
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 16
Contribution Percentage: 41-50

23. Desilets, A; Adam, JP; Soulières, D. (2020). Management of cisplatin-associated toxicities in bladder cancer patients. Current Opinion in Supportive and Palliative Care. 14(3): 286-292.
http://dx.doi.org/10.1097/SPC.0000000000000505
First Listed Author
Published, Wolters Kluwer, Netherlands
Refereed?: Yes, Open Access?: Yes, Synthesis?: Yes
Number of Contributors: 3
Contribution Percentage: 91-100

24. Bourguignon, A; Beaulieu, C; Belkaid, W; Desilets, A; Blais, N. (2020). Incidence of thrombotic outcomes for patients hospitalized and discharged after COVID-19 infection. Thrombosis Research. 196: 491-493.
http://dx.doi.org/10.1016/j.thromres.2020.10.017
Co-Author
Published, Elsevier, Netherlands
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 5
Contribution Percentage: 41-50

25. Desilets, A; Soulières, D. (2020). Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma. Expert Opinion on Drug Safety. 19(8): 927-934.
http://dx.doi.org/10.1016/S0140-6736(18)31999-8
First Listed Author
Published, Taylor and Francis, United Kingdom
Refereed?: Yes, Open Access?: Yes, Synthesis?: Yes
Number of Contributors: 2
Contribution Percentage: 91-100

26. Elkrief, A; Desilets, A; Papneja, N; Cvetkovic, L; Groleau, C; Lakehal, YA; Shbat, L; Richard, C; Malo, J; Belkaid, W; Cook, E; Doucet, S; Tran, TH; Jao, K; Daaboul, N; Bhang, E; Loree, JM; Miller, WH; Vinh, DC; Bouganim, N; Batist, G; Letendre, C; Routy, B. (2020). High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study. European Journal of Cancer. 139: 181-187.
http://dx.doi.org/10.1016/j.ejca.2020.08.017
First Listed Author
Published, Elsevier, Netherlands
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 23
Contribution Percentage: 81-90

27. Desilets, A; Arsenault, F; Laskine, M. (2019). HIV-Infected Patient Diagnosed With Osteomedullary and Hepatic Syphilis on Positron Emission Tomography: A Case Report. Journal of Clinical Medicine Research. 11(4): 301-304.
http://dx.doi.org/10.14740/jocmr3756
First Listed Author
Published, Elmer Press Inc., Canada
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 3
Contribution Percentage: 91-100

28. Desilets, A; Keshavjee, S; Goligher, EC. (2018). Visualizing Heterogeneous Pulmonary Ventilation: Respiratory Failure due to an Anterior Mediastinal Mass. American Journal of Respiratory and Critical Care Medicine. 198(7): e88-e89.
http://dx.doi.org/10.1164/rccm.201801-0037IM
First Listed Author
Published, American Thoracic Society, United States of America
Refereed?: Yes, Synthesis?: No
Number of Contributors: 3
Contribution Percentage: 71-80

Book Chapters

1. Desilets, A; Labossière, M; McGirr, A; Turecki, G. (2016). Schizophrenia, Other Psychotic Disorders, and Suicidal Behavior. The International Handbook of Suicide Prevention. Second Edition: 93-109.
http://dx.doi.org/10.1002/9781118903223.ch5
First Listed Author
Published, Wiley-Blackwell, Oxford, United Kingdom
Refereed?: Yes
Number of Contributors: 3
Contribution Percentage: 81-90

Thesis/Dissertation

1. Inhibiteurs du point de contrôle immunitaire en carcinome pulmonaire : approches immunomodulatrices / Immune checkpoint inhibitors in lung carcinoma: immunomodulatory approaches. (2023). Université de Montréal. Master's Thesis.
Number of Pages: 133 Supervisor: Dr Bertrand Routy
Contribution Percentage: 91-100

Working Papers

1. Co-Author. (Murciano-Goroff, Y R; Nykaza, I; Desilets, A; Harada, G; Postow, M A; Callahan, M K; Lee, C H; Rudin, C M; Kelsen, D P; Stadler, Z K; Wibmer, A G; Hechtman, J F; Drilon, A E; Friedman, C F). (2024). Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors. : 19.
Contribution Percentage: 21-30

2. Co-Author. (Wong, W; Desilets, A; Krishnamoorthy, G P; Sherman, E J; Dunn, L; Kriplani, A; Fetten, J V; Michel, L S; McDonald, E; Grewal, R K; Sabra, M; Boucai, L; Fish, S; Haque, S; Ostrovnaya, I; Ghossein, R A; Fagin, J A; Pfister, D G; Ho, A L). (2024). Durvalumab in combination with radioactive iodine for recurrent or metastatic differentiated thyroid cancer. : 15.
Number of Contributors: 19
Contribution Percentage: 71-80

3. First Listed Author. (Desilets, A; Repetto, M; Yang, S-R; Chen, M F; Novak, B; Velilla, C; Kemel, Y; Selenica, P; Richards, A; Donoghue, M T A; Liu, D; Rosen, E; Khurram, A; Weigelt, B; Li, B T; Yaeger, R; Ladanyi, M; Bandlamudi, C; Liu, Y; Carlo, M; Latham, A; Stadler, Z K; Offit, K; Mandelker, D; Ho, A L; Drilon, A E; Murciano-Goroff, Y R). (2024). PTCH1 mutational landscape and therapeutic outcomes on hedgehog pathway inhibitors in a pan-cancer cohort. : 21.
Number of Contributors: 27
Contribution Percentage: 91-100

4. First Listed Author. (Pang, S A; Desilets, A; Li, M; Hladky, V; del Rincón, S; Jamal, R; Elkrief, A; Miller W H). (2024). Obesity is associated with improved progression-free survival and increased risk of pneumonitis in patients with advanced solid tumours treated with immune checkpoint inhibitors. : 8.
Contribution Percentage: 71-80

Conference Publications

1. Dunn, L; Cracchiolo, J; Ho, A L; Sherman, E J; Ganly, I; Ghossein, R; Cohen, M; Wong, W; Desilets, A; Michel, L; Kriplani, A; Hung, T K W; Singh, B; Boyle, J; Morris, L; McBride, S; Riaz, N; Lee, N; Wong, R; Pfister, D. (2024). Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC). Annals of Oncology. ESMO Annual Meeting 2024, Barcelona, Spain (S619). Elsevier, Netherlands
http://dx.doi.org/10.1016/j.annonc.2024.08.921
Conference Date: 2024/9
Poster
Co-Author
Published
Refereed?: Yes, Invited?: Yes
Number of Contributors: 20
Contribution Percentage: 11-20

2. Desilets, A; Repetto, M; Kemel, Y; Khurram, A; Mandelker, A; Bandlamudi, C; Novak, B; Velilla, C; Selenica, P; Richards, A L; Donoghue, M; Weigelt, B; Ladanyi, M; Li, B T; Yaeger, R; Lito, P; Offit, K; Drilon, A E; Stadler, Z K; Murciano-Goroff, Y R. (2024). Germline and somatic MUTYH mutations: Clinicopathologic and mutational analysis in a pan-cancer cohort. Journal of Clinical Oncology. ASCO Annual Meeting 2024, Chicago, United States of America (10590-10590). Wiley, United States of America
http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.10590
Conference Date: 2024/6
Poster
First Listed Author
Published
Refereed?: Yes, Invited?: Yes
Contribution Percentage: 91-100

3. Soulieres, D; Lucas, J; Desilets, A; Matcovitch-Natan, O; Bart, A; Laniado, A; Gutwillig, A; He, N. Dreyer, K; Rosen Zvi, S; Rachmiel, Z; Kaplan Kerner, J; Yehezkeli, H; Tang, T; Birgerson, L E; Lu, S; Lorch, J; Licitra, L F L. (2023). Utilizing H&E images and digital pathology to predict response to buparlisib in SCCHN. Annals of Oncology. ESMO Annual Meeting 2023, Madrid, Spain (S562). Elsevier, Netherlands
http://dx.doi.org/10.1016/j.annonc.2023.09.2015
Conference Date: 2023/10
Poster
Co-Author
Published
Refereed?: Yes, Invited?: Yes
Number of Contributors: 18
Contribution Percentage: 41-50

4. Desilets, A; Hermosilla Samayoa, C; Tonneau, M; El Ouarzadi, O; De Figueiredo Sousa, M; Bahig, H; Malo, J; Belkaid, W; Benlaïfaoui, M; Ponce, M; Derosa, L; Filion, E; Nguyen-Tan, P. F; Charpentier, D; Aubin, F M; Hamilou, Z; Jamal, R; Routy, B; Messaoudene, M; Soulieres, D. (2023). Gut microbiome metagenomics and toxicity outcomes from chemoradiation therapy in head and neck squamous cell carcinoma. Annals of Oncology. ESMO Annual Meeting 2023, Madrid, Spain (S574). Elsevier, Netherlands
http://dx.doi.org/10.1016/j.annonc.2023.09.2046
Conference Date: 2023/10
Poster
First Listed Author
Published
Refereed?: Yes, Invited?: Yes
Contribution Percentage: 81-90

5. Desilets, A; Wong, W; Krishnamoorthy, G P; Sherman, E J; Dunn, L; Kriplani, A; Fetten, J V; Michel, L S; McDonald, E; Grewal, R K; Sabra, M; Boucai, L; Fish, S; Haque, S; Ostrovnaya, I; Ghossein, R A; Fagin, J A; Pfister, D G; Ho, A L. (2023). Durvalumab in combination with radioactive iodine in recurrent/metastatic thyroid cancers: Update on clinical and correlative analyses. Clinical Cancer Research. AACR-AHNS Annual Meeting 2023, Montreal, Canada. American Association for Cancer Research, United States of America
http://dx.doi.org/10.1158/1557-3265.AACRAHNS23-PO-072
Conference Date: 2023/7
Poster
First Listed Author
Published
Refereed?: Yes, Invited?: Yes
Number of Contributors: 19
Contribution Percentage: 71-80

6. Chen, M F; Yang, S-R; Tao, J; Desilets, A; Rosen, E; Gong, Y; Mullaney, K A; Kris, M G; Arcila, M E; Donoghue, M; Somwar, R; Ladanyi, M; Rosen, N; Yaeger, R; Drilon, A E; Offin, M; Murciano-Goroff, Y R. (2023). Tumor-agnostic genomic and clinical analysis of solid tumors with BRAF fusions. Journal of Clinical Oncology. ASCO Annual Meeting 2023, Chicago, United States of America (3146-3146). Wiley, United States of America
http://dx.doi.org/10.1200/JCO.2023.41.16_suppl.3146
Conference Date: 2023/6
Poster
Co-Author
Published
Refereed?: Yes, Invited?: Yes
Number of Contributors: 17
Contribution Percentage: 21-30

7. Desilets, A; Pfister, D G; Wong, W; Sherman, E J; Fetten, J V; Hung, K W; Dunn, L; Ho, A L; Michel, L S. (2023). A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer. Journal of Clinical Oncology. ASCO Annual Meeting 2023, Chicago, United States of America (6025-6025). Wiley, United States of America
http://dx.doi.org/10.1200/JCO.2023.41.16_suppl.6025
Conference Date: 2023/6
Poster
Co-Author
Published
Refereed?: Yes, Invited?: Yes
Number of Contributors: 9
Contribution Percentage: 71-80

8. Desilets, A; Beland, C; Hladky, V; Pang, S A; Elkrief, A; Stepanov, A; Routy, B; Belanger, K; Miller, W H; Larochelle, O; Jamal, R. (2022). Uveal melanoma: Real-world analysis of immune checkpoint inhibitors efficacy and lymphocyte-to-monocyte ratio as a biomarker of response. Journal of Clinical Oncology. ASCO Annual Meeting 2022, Chicago, United States of America (e21590-e21590). Wiley, United States of America
http://dx.doi.org/10.1200/JCO.2022.40.16_suppl.e21590
Conference Date: 2022/6
Abstract
First Listed Author
Published
Refereed?: Yes, Invited?: No
Number of Contributors: 11
Contribution Percentage: 81-90

9. Deschenes-Simard, X; Galland, L; Blais, F; Desilets, A; Malo, J; Cvetkovic, L; Belkaid, W; Elkrief, A; Gagné, A; Hamel, M-A; Orain, M; Joubert, P; Ghiringhelli, F; Routy, B; Blais, N. (2021). Thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study. Journal of Clinical Oncology. ASCO Annual Meeting 2021, Virtual, United States of America (e21198-e21198). Wiley, United States of America
http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.e21198
Conference Date: 2021/6
Abstract
Co-Author
Published
Refereed?: Yes, Invited?: No
Number of Contributors: 15
Contribution Percentage: 21-30

10. Richard, C; Benlaifaoui, M; El Ouarzadi, O; Diop, K; Desilets, A; Malo, J; Belkaid, W; Leblanc, A; Lamontagne, J; Messaoudene, M; Elkrief, A; Routy, B. (2020). High fiber diet modifies gut microbiome, propionate production, intratumor immune response and is associated with outcome in patients with lung cancer treated with immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. Society for Immunotherapy of Cancer 2020, Virtual, United States of America (A408). BMJ Publishing Group, United Kingdom
http://dx.doi.org/10.1136/jitc-2020-SITC2020.0679
Conference Date: 2020/11
Poster
Co-Author
Published
Refereed?: Yes, Invited?: Yes
Number of Contributors: 12
Contribution Percentage: 11-20

11. Desilets, A; Aubin, F; Bahig, H; Ballivy, O; Charpentier, D; Filion, E; Jamal, R; Lambert, L; Vadnais, C; Weng, X; Soulières, D. (2020). Upfront DPYD genotyping and toxicity associated with fluoropyrimidine-based concurrent chemoradiotherapy for oropharyngeal carcinomas. Journal of Clinical Oncology. ASCO Annual Meeting 2020, Chicago, United States of America (6580-6580). Wiley, United States of America
http://dx.doi.org/10.1200/JCO.2020.38.15_suppl.6580
Conference Date: 2020/5
Poster
First Listed Author
Published
Refereed?: Yes, Invited?: Yes
Number of Contributors: 11
Contribution Percentage: 81-90

12. Desilets, A; Aubin, F; Amireault, C; Ayoub, J P M; Letourneau, L; Tehfe, M. (2018). Pancreatic adenocarcinoma in young adults: characteristics and clinical outcomes from a Canadian Center. Journal of Clinical Oncology. ASCO GI Annual Meeting 2018, San Francisco, United States of America (260-260). Wiley, United States of America
http://dx.doi.org/10.1200/JCO.2018.36.4_suppl.260
Conference Date: 2018/1
Poster
First Listed Author
Published
Refereed?: Yes, Invited?: Yes
Number of Contributors: 6
Contribution Percentage: 91-100

Protected when completed

Dr. Alexandre Pellan Cheng

Correspondence language: English
Sex: Male
Date of Birth: 2/09
Canadian Residency Status: Canadian Citizen
Country of Citizenship: Canada

Contact Information

The primary information is denoted by (*)

Address

Home (*)

333 Boul. Clairevue E
1301
St-Bruno Quebec J3V6R5
Canada

Telephone

Mobile (*)	514-942-7091

Email

Work (*)	alexandre.pellan-cheng@etsmtl.ca

Dr. Alexandre Cheng

Language Skills

Language	Read	Write	Speak	Understand	Peer Review
English	Yes	Yes	Yes	Yes	Yes
French	Yes	Yes	Yes	Yes	Yes

Degrees

2016/8 - 2021/8
Doctorate, Ph.D in Biomedical Engineering, Biomedical Engineering, Cornell University
Degree Status: Completed

Supervisors: Iwijn De Vlaminck, 2016/8 - 2021/8

2012/8 - 2016/5
Bachelor's, Bachelors of Engineering, Biomedical Engineering, École Polytechnique de Montréal
Degree Status: Completed

Supervisors: Caroline Hoemann, 2013/5 - 2016/8

Recognitions

2024/1 - 2024/10
American Cancer Society Postdoctoral Fellowship - 302,000
American Cancer Society
Prize / Award
I was awarded a postdoctoral fellowship award. However, my fellowship was cancelled in order for me to begin my associate professorship.

2023/1 - 2023/12
Innovation & Discovery Award - 2,000 (United States dollar)
New York Genome Center
Prize / Award
The Innovation & Discovery Award is awarded to individuals who develop new innovative scientific or business ideas, projects or cost savings and use creativity and ingenuity to continuously pursue improvements that positively impact the Center. All individuals from any discipline have an opportunity to innovate, so we welcome nominees from all groups across NYGC.

2018/5 - 2021/5
NSERC Postgraduate Scholarship - 63,000 (Canadian dollar)
Natural Sciences and Engineering Research Council of Canada (NSERC)
Prize / Award
The NSERC Postgraduate Scholarships – Doctoral (PGS D) program provides financial support to high-calibre students who are engaged in an eligible doctoral program in natural sciences and engineering. Specifically, my proposed research was to utilize cell-free DNA methylation patterns as a novel biomarker for Graft-versus-Host Disease.

2016/8
De Vinci Profile
École Polytechnique de Montréal

2016/8 - 2017/5	Fischell Graduate Scholarship in Bioengineering Cornell University Prize / Award Awarded to graduate students
2014/1	Motility Scholarship for Exchange Students Quebec Government
2013/8	AACE International scholarship Association for the Advancement of Cost Engineering
2013/8	École Polytechnique de Montréal Research Initiation Grant École Polytechnique de Montréal
2012/8	École Polytechnique de Montréal Entry Scholarship École Polytechnique de Montréal
2012/8 - 2016/5	Mention of Academic Excellence École Polytechnique de Montréal
2012/5	Marianopolis Scolar Marianopolis College

User Profile

Research Specialization Keywords: Bioinformatics, Molecular engineering, Genomics, Machine learning, Cell-free DNA, Circulating tumor DNA, Cancer detection, Liquid biopsy, Biotechnology development, Signal-to-noise enhancement, Noninvasive diagnostics

Disciplines Trained In: Genetics

Employment

2021/9 - 2024/10	Postdoctoral Associate Medicine, Medicine, Cornell University Medical College Full-time Tenure Status: Non Tenure Track As a postdoctoral associate funded by the American Cancer Society, I developed noninvasive liquid biopsies for cancer detection. I also engaged in unofficial mentorship, grant writing and manuscript preparation.
2022/1 - 2023/6	Scientific consultant for technology transfer Eurofins-Viracor; Lenexa, Kansas I assisted Eurofins-Viracor scientists in implementing laboratory and bioinformatic workflows pertaining to three licensed patents on which I am listed as an inventor (US patent numbers 63/056,249, 63/015,095 and 16/500,929).
2022/12 - 2022/12	Scientific consultant for technology evaluation Karius; Redwood City, California I performed bioinformatic analysis and assisted in implementing the laboratory protocol for a next-generation sequencing assay I co-invented (US patent application 63/237,367)

2016/8 - 2021/8	Graduate Research Assistant (Ph.D. researcher) Biomedical Engineering, Engineering, Cornell University Full-time Tenure Status: Non Tenure Track As an NSERC PGS D-funded graduate student, I developed cell-free DNA based whole genome assays and accompanying bioinformatic workflows to characterize infectious and immune diseases. I also participated in unofficial mentorship of undergraduate and graduate students, aided in grant writing and disseminated my work through peer-reviewed publications.
2013/5 - 2016/8	Research Assistant Chemical Engineering, Chemical Engineering, École Polytechnique de Montréal Full-time Tenure Status: Non Tenure Track As an USRA-funded undergraduate researcher, I designed and implemented assays to characterize the immune-modulating properties of chitosans.
2015/5 - 2015/8	Research Assistant Infectious disease, Medicine, McGill University Health Centre Part-time Tenure Status: Non Tenure Track At the McGill University Health Center, I studied how *Staphylococcus aureus*, a common pathogen, may lose antibiotic resistance over time.

Affiliations

The primary affiliation is denoted by (*)

(*) 2025/1	Associate Professor, École de technologie supérieure
2025/1	Principal scientist, Centre hospitalier de l'Université de Montréal

Research Funding History

Completed [n=1]

2024/1 - 2024/10 Principal Investigator	Whole-genome error corrected sequencing for early stage melanoma detection without matched tumors, Fellowship Project Description: Cancer monitoring tools are underdeveloped, but liquid biopsies aim to revolutionize this space by profiling for disease from circulating tumor DNA (ctDNA; DNA that is shed from tumor cells and enters the circulation). Many tools rely on sequencing a patient's tumor to create a list of mutations to mine for in the blood. Therefore, patients with scant or unavailable tumor material cannot be monitored with current methods. I propose to develop error-corrected whole genome sequencing to monitor patients without matched tumor sequencing. The principle behind my research is that dramatically reducing the error rate of sequencing technologies (currently ~1:1000) will allow for the robust identification of cancer mutations from ctDNA alone. For example, we will be able to profile for characteristic mutations of ultraviolet light induced DNA mutations in the plasma of skin cancer patients, and differentiate those mutations from aging related mutations in the plasma.

Funding Sources:

American Cancer Society
Postdoctoral Fellowship
Total Funding - 302,000
Portion of Funding Received - 91,000
Funding Competitive?: Yes

Under Review [n=1]

2025/4 - 2028/4
Principal Applicant

Cell-free DNA for the Management of Patients with Staphylococcus aureus Bacteremia: The Cell-free DNA Pilot Study Within the Staphylococcus aureus Network Adaptive Platform (DNA-SNAP), Grant

Funding Sources:

Canadian Institutes of Health Research (CIHR)
Total Funding - 980,000
Portion of Funding Received - 0
Funding Competitive?: Yes

Courses Taught

Teaching assistant, Cornell University
Course Title: Electrical and Chemical Physiology
Course Code: BME4020
Academic Session: Spring

Course Development

Teaching Assistant, Cornell University
Course Title: Electrical and Chemical Physiology
Course Level: Undergraduate

Student/Postdoctoral Supervision

Bachelor's [n=2]

2018/8 - 2020/8
Co-Supervisor

Jonathan Han (Completed) , Cornell University
Thesis/Project Title: Developing a digital PCR assay to quantify tissue injury using cell-free DNA. As a PhD student under the supervision of Iwijn De Vlaminck, PhD, I co-supervised Jonathan Han.
Present Position: Medical student

2017/8 - 2018/2
Co-Supervisor

Bashta, Michael (Completed) , Cornell University
Thesis/Project Title: Developing a CRISPR-based assay to detect tissue of origin in cell-free DNA. As a PhD student under the supervision of Iwijn De Vlaminck, PhD, I co-supervised Michael Bashta.
Present Position: Flight instructor

Master's Equivalent [n=1]

2020/8 - 2021/8 Co-Supervisor	Sami Smalling (Completed) , Cornell University Thesis/Project Title: Computational tools to filter contaminants from next-generation sequencing experiments. As a PhD student under the supervision of Iwijn De Vlaminck, PhD, I co-supervised Sami Smalling. Present Position: Data Scientist at Noblis

Doctorate [n=1]

2022/8 - 2024/10 Co-Supervisor	Srinivas Rajagopalan (In Progress) , Weill Cornell Medical College Thesis/Project Title: Novel targeted sequencing method for sensitive tumor burden detection via multi-omic circulating tumor DNA features. As a postdoctoral associate under the supervision of Dan-Avi Landau, MD, PhD, I co-supervised Srinivas Rajagopalan. Present Position: PhD candidate, Weill Cornell Medical College

Research Associate [n=3]

2022/8 - 2024/7 Co-Supervisor	Aaron Sossin, New York Genome Center Thesis/Project Title: Novel bioinformatic tools for next generation sequencing platforms. As a postdoctoral associate under the supervision of Dan-Avi Landau MD, PhD, I co-supervised Aaron Sossin. Present Position: PhD student, Columbia University
2022/5 - 2024/5 Co-Supervisor	Clayton Hughes, Weill Cornell Medical College Thesis/Project Title: Error-corrected library preparation for degraded DNA. As a postdoctoral associate under the supervision of Dan-Avi Landau MD, PhD, I co-supervised Anushri Arora Present Position: Ph.D. student, Columbia University
2021/9 - 2023/8 Co-Supervisor	Anushri Arora, New York Genome Center Thesis/Project Title: AI-guided error suppression from next-generation sequencing reads. As a postdoctoral associate under the supervision of Dan-Avi Landau, MD, PhD, I co-supervised Anushri Arora. Present Position: PhD student at Princeton University

Editorial Activities

2021/10 - 2021/10	Author, Lightning does strike twice: Leveraging phased variants to enhance minimal residual disease detection. Med., Journal
2018/12 - 2018/12	Author, Biopsy-free screening for glioma. EMBO Molecular Medicine., Journal

Knowledge and Technology Translation

2022/1 - 2023/6	Scientific Consultant, Technology Transfer and Commercialization Target Stakeholder: Industry/Business (>500 employees) Outcome / Deliverable: Technology transfer of intellectual property Activity Description: Scientific consultation after Eurofins-Viracor acquired 3 licenses for patents for which I am an inventor. Patents were filed during graduate studies.

International Collaboration Activities

2023/1 - 2024/11 Project supervisor, United Kingdom
Here, I co-supervise a project seeking to develop a next-generation sequencing assay for non-cancerous somatic disease. This collaborative project joins research teams from New York (Weill Cornell Medical College and the New York Genome Center) with laboratories in Texas (University of Texas Southwestern), Miami (the University of Miami), and the United Kingdom (Wellcome Sanger Institute, University of Oxford)

2021/9 - 2024/11 Project lead, United States of America
This international collaboration included research centers in New York (Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and the New York Genome Center), the Massachusetts General Hospital and the United Kingdom (The Francis Crick Institute, The Royal Marsden NHS Foundation Trust). Here, I developed a whole genome error-corrected sequencing assay for circulating tumor DNA monitoring.

2020/8 - 2022/7 Project lead, United States of America
This international collaboration between Cornell University, Weill Cornell Medical College, NewYork PResbytarian Hospital and the Infectious Disease Research Collaboration in Uganda sought to develop a metagenomic DNA sequencing assay that is robust to environmental DNA contamination and improves the specificity of infection diagnosis.

2018/8 - 2022/1 Project lead, United States of America
In this collaboration, I developed a cell-free DNA assay and bioinformatic pipeline designed to inform major complications of stem cell transplants. This work was led by Cornell University with the Dana Farber Cancer Institute and Brigham and Women's Hospital in Massachusetts.

2020/2 - 2021/4 Project lead, United States of America
Co-lead on an international COVID-19 discovery project where I utilized my previously developed whole-genome methylation sequencing assay to tissue damage related to COVID-19 severity. This collaboration included Cornell University, the University of California in San Francisco and McGill University.

2016/8 - 2019/9 Project lead, United States of America
I developed a cell-free DNA metagenomic sequencing assay to profile the host injury response to infection in patients receiving a kidney transplant. This collaboration was between Cornell University and physicians at NewYork Presbytarian Hospital in New York, New York.

Presentations

1. (2024). Whole genome sequencing for circulating tumor DNA detection. Circulating Nucleic Acids in Plasma and Serum, Austria
   Main Audience: Researcher
   Invited?: Yes, Keynote?: No
2. (2023). Whole genome error-corrected sequencing for sensitive circulating tumor DNA cancer monitoring.American Association for Cancer Research, United States of America
   Main Audience: Researcher
   Invited?: No, Keynote?: No

3. (2022). Deep and error corrected sequencing via the low-cost Ultima Genomics platform enables ultra-sensitive circulating tumor DNA cancer monitoring. American Society of Human Genetics, United States of America
   Main Audience: Researcher
   Invited?: No, Keynote?: No
4. (2020). Cell-free DNA Tissues of Origin Profiling To Monitor Infections and Immune-related Disease.Biomedical Engineering Society, United States of America
   Main Audience: Researcher
   Invited?: No, Keynote?: No
5. (2020). Liquid biopsies for infectious and immune diseases. University of Montreal, Canada
   Main Audience: Researcher
   Invited?: Yes, Keynote?: No
6. (2020). Cell-free DNA tissues-of-origin profiling to monitor infectious and immune-related disease. American Society of Human Genetics, United States of America
   Main Audience: Researcher
   Invited?: No, Keynote?: No
7. (2020). Liquid biopsies for infectious and immune diseases. McGill University, Canada
   Main Audience: Researcher
   Invited?: Yes, Keynote?: No
8. (2020). Liquid biopsies for infectious and immune diseases. Hackensack Meridian Health Center for Discovery and Innovation, United States of America
   Main Audience: Researcher
   Invited?: Yes, Keynote?: No
9. (2020). A metagenomic sequencing assay that integrates the host-damage response to infection. The Biology of Genomes, United States of America
   Main Audience: Researcher
   Invited?: No, Keynote?: No
10. (2019). A cell-free DNA metagenomic sequencing assay to simultaneously profile infection and tissue damage.Circulating Nucleic Acids in Serum and Plasma, Israel
    Main Audience: Researcher
    Invited?: No, Keynote?: No
11. (2019). A cell-free DNA metagenomic sequencing assay that integrates the damage response to infection.New England BK Convention, United States of America
    Main Audience: Researcher
    Invited?: Yes, Keynote?: No
12. (2018). Distinguishing infection from infectious disease using methylation marks comprised within cell-free DNA.American Society of Human Genetics, United States of America
    Main Audience: Researcher
    Invited?: No, Keynote?: No

Text Interviews

2020/10/26 Cell-Free DNA provides a dynamic window into health, American Society of Human Genetics
https://www.eurekalert.org/news-releases/510723
Description / Contribution Value: I provided a text interview with the American Society of Human Genetics on my oral presentation (Cheng, A.P., Burnham, P., Cheng, M.P., Chen, K., Dadhania, D., Gu, W., Lee, J.R., Lenz, J.S., Marty, F.M., Orejas, J.L., Silverman, E., Suthanthiran, M., Timblin, K.M., Ritz, J., and De Vlaminck, I. (Date). Abstract: Cell-free DNA tissues-of-origin profiling to monitor infectious and immune-related disease. Presented at the American Society of Human Genetics 2020 Virtual Meeting.). The goal of the text interview was to render my project results more accessible to a general audience.

Publications

Journal Articles

1. Adam J Widman, Minita Shah, Nadia Øgaard, Cole C Khamnei, Amanda Frydendahl, Aditya Deshpande, Anushri Arora, Mingxuan Zhang, Daniel Halmos, Jake Bass, Theophile Langanay, Srinivas Rajagopalan, Zoe Steinsnyder, Will Liao, Mads Heilskov Rasmussen, Sarah Østrup Jensen, Jesper Nors, Christina Therkildsen, Jesus Sotelo, Ryan Brand, Ronak H Shah, Alexandre Pellan Cheng, Colleen Maher, Lavinia Spain, Kate Krause, Dennie T Frederick, Murtaza S Malbari, Melissa Marton, Dina Manaa, Lara Winterkorn, Margaret K Callahan, Genevieve Boland, Jedd D Wolchok, Ashish Saxena, Samra Turajlic, Marcin Imielinski, Michael F Berger, Nasser K Altorki, Michael A Postow, Nicolas Robine, Claus Lindbjerg Andersen, Dan A Landau. (2024). Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment. Nature Medicine. NA: NA.
Accepted,
Refereed?: Yes, Open Access?: No

2. Conor J Loy, Alicia Sotomayor-Gonzalez, Venice Servellita, Jenny Nguyen, Joan Lenz, Sanchita Bhattacharya, Meagan E Williams, Alexandre P Cheng, Andrew Bliss, Prachi Saldhi, Noah Brazer, Jessica Streithorst, William Suslovic, Charlotte J Hsieh, Burak Bahar, Nathan Wood, Abiodun Foresythe, Amelia Gliwa, Kushmita Bhakta, Maria A Perez, Laila Hussaini, Evan J Anderson, Ann Chahroudi, Meghan Delaney, Atul J Butte, Roberta L DeBiasi, Christina A Rostad, Iwijn De Vlaminck, Charles Y Chiu. (2023). Nucleic acid biomarkers of immune response and cell and tissue damage in children with COVID-19 and MIS-C. Cell Reports Medicine. 4: 1-23.
Published,
Refereed?: Yes

3. Adrienne Chang, Omary Mzava, Joan S Lenz, Alexandre P Cheng, Philip Burnham, S Timothy Motley, Crissa Bennett, John T Connelly, Darshana M Dadhania, Manikkam Suthanthiran, John R Lee, Amy Steadman, Iwijn De Vlaminck. (2022). Measurement biases distort cell-free DNA fragmentation profiles and define the sensitivity of metagenomic cell-free DNA sequencing assays. Clinical Chemistry. 68: 163-171.
Published,
Refereed?: Yes, Open Access?: Yes

4. Omary Mzava, Alexandre Pellan Cheng, Adrienne Chang, Sami Smalling, Liz-Audrey Kounatse Djomnang, Joan Sesing Lenz, Randy Longman, Amy Steadman, Luis G Gómez-Escobar, Edward J Schenck, Mirella Salvatore, Michael J Satlin, Manikkam Suthanthiran, John R Lee, Christopher E Mason, Darshana Dadhania, Iwijn De Vlaminck. (2022). A metagenomic DNA sequencing assay that is robust against environmental DNA contamination. Nature Communications. 13(1): 4197.
Published,
Refereed?: Yes, Open Access?: Yes

5. Ramya Chandrasekaran, Colleen Mathieu, Rishi Sheth, Alexandre P Cheng, David Fong, Robert McCormack, Hani El-Gabalawy, Suman Alishetty, Mikell Paige, Caroline D Hoemann. (2022). UDP-glucose dehydrogenase (UGDH) activity is suppressed by peroxide and promoted by PDGF in fibroblast-like synoviocytes: Evidence of a redox control mechanism. Plos one. 17: e0274420.
Published,
Refereed?: Yes, Open Access?: Yes

6. Philip Burnham, Fanny Chen, Alexandre P Cheng, Vesh Srivatana, Lisa T Zhang, Emmanuel Edusei, Shady Albakry, Brittany Botticelli, Xunxi Guo, Amanda Renaghan, Jeffrey Silberzweig, Darshana M Dadhania, Joan S Lenz, Michael Heyang, Iliyan D Iliev, Joshua A Hayden, Lars F Westblade, Iwijn De Vlaminck, John R Lee. (2022). Peritoneal effluent cell-free DNA sequencing in peritoneal dialysis patients with and without peritonitis. Kidney Medicine. 4: 100383.
Published,
Refereed?: Yes, Open Access?: Yes

7. Alexandre Pellan Cheng, Matthew Pellan Cheng, Conor James Loy, Joan Sesing Lenz, Kaiwen Chen, Sami Smalling, Philip Burnham, Kaitlyn Marie Timblin, José Luis Orejas, Emily Silverman, Paz Polak, Francisco M Marty, Jerome Ritz, Iwijn De Vlaminck. (2022). Cell-free DNA profiling informs all major complications of hematopoietic cell transplantation. Proceedings of the National Academy of Sciences. 119: e2113476118.
Published,
Refereed?: Yes, Open Access?: Yes

8. Alexandre Pellan Cheng, Adam J Widman, Anushri Arora, Itai Rusinek, William F Hooper, Rebecca Murray, Daniel Halmos, Theophile Langanay, Giorgio Inghirami, Soren Germer, Melissa Marton, Dina Manaa, Adrienne Helland, Rob Furatero, Jaime McClintock, Lara Winterkorn, Zoe Steinsnyder, Yohyoh Wang, Srinivas Rajagopalan, Asrar I Alimohamed, Murtaza S Malbari, Ashish Saxena, Margaret K Callahan, Dennie T Frederick, Lavinia Spain, Ariel Jaimovich, Doron Lipson, Samra Turajlic, Michael C Zody, Nasser K Altorki, Jedd D Wolchok, Michael A Postow, Nicolas Robine, Genevieve Boland, Dan A Landau. (2022). Whole genome error-corrected sequencing for sensitive circulating tumor DNA cancer monitoring. Nature Methods. NA: NA.
Revision Requested,
Refereed?: No, Open Access?: No

9. AP Cheng, DA Landau. (2021). Lightning does strike twice: leveraging phased variants to enhance minimal residual disease detection. Med. 2: 1114-1116.
Published,
Refereed?: No, Open Access?: Yes

10. Alexandre Pellan Cheng, Matthew Pellan Cheng, Wei Gu, Joan Sesing Lenz, Elaine Hsu, Erwin Schurr, Guillaume Bourque, Mathieu Bourgey, Jerome Ritz, Francisco M Marty, Charles Y Chiu, Donald C Vinh, Iwijn De Vlaminck. (2021). Cell-free DNA tissues of origin by methylation profiling reveals significant cell, tissue, and organ-specific injury related to COVID-19 severity. Med. 2: 411-422.
Published,
Refereed?: Yes, Open Access?: Yes

11. Philip Burnham, Nardhy Gomez-Lopez, Michael Heyang, Alexandre Pellan Cheng, Joan Sesing Lenz, Darshana M Dadhania, John Richard Lee, Manikkam Suthanthiran, Roberto Romero, Iwijn De Vlaminck. (2020). Separating the signal from the noise in metagenomic cell-free DNA sequencing. Microbiome. 8: 1-9.
Published,
Refereed?: Yes, Open Access?: Yes

12. Matthew P Cheng, Robyn S Lee, Alexandre P Cheng, Samuel De L'Étoile-Morel, Koray Demir, Cedric P Yansouni, Patrick Harris, Emily G McDonald, Todd C Lee. (2019). Beta-lactam/beta-lactamase inhibitor therapy for potential AmpC-producing organisms: a systematic review and meta-analysis. Open forum infectious diseases. 6: ofz248.
Published,
Refereed?: Yes, Open Access?: Yes

13. Alexandre Pellan Cheng, Philip Burnham, John Richard Lee, Matthew Pellan Cheng, Manikkam Suthanthiran, Darshana Dadhania, Iwijn De Vlaminck. (2019). A cell-free DNA metagenomic sequencing assay that integrates the host injury response to infection. Proceedings of the National Academy of Sciences. 116: 18738-18744.
Published,
Refereed?: Yes, Open Access?: Yes

14. Alexandre Pellan Cheng, Philip Burnham, Iwijn De Vlaminck. (2018). Biopsy-free screening for glioma. EMBO molecular medicine. 10: e9484.
Published,
Refereed?: No, Open Access?: Yes

15. David Fong, Pascal Grégoire-Gélinas, Alexandre P Cheng, Tal Mezheritsky, Marc Lavertu, Sachiko Sato, Caroline D Hoemann. (2017). Lysosomal rupture induced by structurally distinct chitosans either promotes a type 1 IFN response or activates the inflammasome in macrophages. Biomaterials. 129: 127-138.
Published,
Refereed?: Yes, Open Access?: Yes

Intellectual Property

Patents

1. Contamination-Free Metagenomic DNA Sequencing. United States of America. US PROV. USSN 63/237,367. 2024/02/23.
Patent Status: Pending
Inventors: Iwijn De Vlaminck, Alexandre Cheng, Omary Mzava, Adrienne Chang

2. Nucleic acid error correction. United States of America. PCT/US23/35877. 2023/10/25.
Patent Status: Pending
Inventors: Alexandre Pellan Cheng Dan-Avi Landau

3. Methods for assessing the severity and progression of sars-cov2 infections using cell-free dna. United States of America. WO2022020662A2. 2021/07/23.
Patent Status: Pending
Inventors: Iwijn De Vlaminck Alexandre Pellan Cheng Matthew Cheng Doh Vinh Wei Gu Charles Chiu

4. Methods for detecting tissue damage, graft versus host disease, and infections using cell-free dna profiling. United States of America. WO2021216985A2. 2021/04/23.
Patent Status: Pending
Inventors: Iwijn De Vlaminck Alexandre Pellan Cheng Matthew Pellan Cheng Francisco Marty Jerome Ritz

5. Methods of detecting cell-free dna in biological samples. United States of America. US20240026456A1. 2018/04/05.
Patent Status: Granted/Issued
Inventors: Iwijn De Vlaminck John Richard Lee Philip Smith Burnham Alexandre Pellan Cheng Manikkam Suthanthrian Darshana M Dadhania

Protected when completed

Date Submitted: 2025-02-06 14:18:14
Confirmation Number: 1907161
Template: Full CV

Dr. Bertrand Routy

Correspondence language: English
Sex: Male
Date of Birth: 1/21
Canadian Residency Status: Canadian Citizen
Country of Citizenship: Canada

Contact Information

The primary information is denoted by (*)

Address

Primary Affiliation (*)

CENTRE DE RECHERCHE DU CHUM
900 Rue Saint-Denis
Montreal Quebec H2X 0A9
Canada

Telephone

Mobile (*)	+1-514-581-8381

Email

Work (*)	bertrand.routy@umontreal.ca

Protected when completed

Dr. Bertrand Routy

Language Skills

Language	Read	Write	Speak	Understand	Peer Review
English	Yes	Yes	Yes	Yes	Yes
French	Yes	Yes	Yes	Yes	Yes

Degrees

2014/10 - 2017/11

Doctorate, PhD. Degree, immuno-oncology, Université de Paris XI (Paris-Sud)
Degree Status: Completed
Thesis Title: Contribution of gut microbiota on systemic response to anticancer immunomodulatory drugs

Supervisors: Pr. Laurence Zitvogel, 2014/10 - 2017/9

Research Disciplines: Oncology

Areas of Research: Lung Cancer

Fields of Application: Pathogenesis and Treatment of Diseases

2012/9 - 2014/7

Diploma, Residency, Hematology, University of Toronto
Degree Status: Completed
Thesis Title: Hematology

Supervisors: ND

2009/9 - 2012/7

Diploma, Residency, Internal medicine, McGill University
Degree Status: Completed
Thesis Title: Hematology

Supervisors: ND

2005/9 - 2009/6

Doctorate, medical degree, Doctor of Medicine, Université de Montréal
Degree Status: Completed
Thesis Title: Medical degree

Supervisors: ND

2003/9 - 2005/6

Bachelor's, Bachelor of Science, Biochemistry, McGill University
Degree Status: Completed
Thesis Title: Biochemistry

Supervisors: ND

Research Disciplines: Biochemistry

Areas of Research: Biological and Biochemical Mechanisms

Recognitions

2023/12
Doctor of the year
Quebec College of Physicians
Prize / Award
"Coup de Cœur" distinction of the "Collège des Médecins du Québec"

2023/12
Joe Doupe Young Investigator Award
Canadian Society for Clinical Investigation
Prize / Award
CSCI University of Manitoba - Joe Doupe Young Investigator Award

2023/12
CRCHUM Scientific Contribution of the Year category
CRCHUM
Prize / Award
2023 Award of Excellence in the Scientific Contribution of the Year category

2023/6
ASCO award Chicago
American Society of Clinical Oncology
Prize / Award
ASCO award Chicago

2023/4 - 2027/4
Research scholar Junior 2 Ranked #1
Fonds de recherche du Québec - Santé (FRQS)
Prize / Award
Clinician-Scientist Junior 2 Ranked #1

2022/11
Prix de la relève scientifique
Gouvernement du Québec
Prize / Award
Prix de la rélève scientifique du Québec

2022/6
Star of the CHUM for medical education
CHUM
Prize / Award
Star of the CHUM for medical education

2022/4
Cancer Immunology Research Journal: Most cited article in 2020
Cancer Immunology Research - AACR Journals
Prize / Award
Cancer Immunology Research Journal: Most cited article in 2020

2022/1 - 2027/1
Tier 2 Canada Research Chair of Immunology (DECLINED)
Government of Canada
Prize / Award
Tier 2 Canada Research Chair of Immunology

2021/9
Gairdner award - Early Career Investigator Competition
Canada Gairdner foundation
Prize / Award
Gairdner award - Early Career Investigator Competition

2021/3
Prize for the Best Young Investigator
Université de Montréal
Prize / Award
Prize for the Best young investigator

2021/1	Best young Investigator Award - CRCHUM Centre hospitalier de l'Université de Montréal Prize / Award Young Investigator Award - CRCHUM
2021/1	Prix du meilleur jeune chercheur de la faculté de médecine de l'Université de Montréal. Centre hospitalier de l'Université de Montréal Prize / Award Prix du meilleur jeune chercheur de la faculté de médecine de l'Université de Montréal.
2019/4 - 2023/4	Clinician-Scientist Junior 1 Ranked #1 Fonds de recherche du Québec - Santé (FRQS) Prize / Award Clinician-Scientist Junior 1 Ranked #1
2018/6	Conquer Cancer Foundation Merit Award - American Society of Clinical Oncology (ASCO) 2018 ASCO Prize / Award ASCO 2018 Merit award
2018/1	Article of the year in Sciences & Avenir - La recherche Sciences & Avenir - La recherche journal Prize / Award Article of the year in Sciences & Avenir - La recherche Areas of Research: Lung Cancer Fields of Application: Pathogenesis and Treatment of Diseases
2017/6	Conquer Cancer Foundation Merit Award - American Society of Clinical Oncology (ASCO) 2017 ASCO Prize / Award Conquer Cancer Foundation Merit Award - American Society of Clinical Oncology (ASCO) 2017 Research Disciplines: Oncology Areas of Research: Lung Cancer Fields of Application: Health System Management
2017/6 - 2017/6	Genitourinary Conquer Cancer Foundation Merit Award - American Society of Clinical Oncology (ASCO) 2017 ASCO Genitourinary Prize / Award Genitourinary Conquer Cancer Foundation Merit Award - American Society of Clinical Oncology (ASCO) 2017 Research Disciplines: Oncology Areas of Research: Cancer of the Urinary System

2015/1 - 2015/1	Canadian Hematology Society research Abstract award RK Smiley Research Grant program Prize / Award Canadian Hematology Society research Abstract award Research Disciplines: Hematology Areas of Research: Hematology Fields of Application: Biomedical Aspects of Human Health
2014/10 - 2017/9	Townsend hematology research fellowship scholarship Université de Montréal Honor Townsend hematology research fellowship scholarship
2014/10 - 2017/9	Montreal General Hospital foundation research scholarships Montreal General Hospital Honor Montreal General Hospital foundation research scholarships
2014/10 - 2017/9	Course of excellence in oncology - Fondation Philanthropia Institut Gustave-Roussy Honor Fondation Philanthropia- Course of excellence in oncology Research Disciplines: Oncology Areas of Research: Host-Tumour Interaction Fields of Application: Biomedical Aspects of Human Health
2014/9 - 2015/9	France Canada Research Fund France Canada Research Fund Honor France Canada Research Fund
2013/1 - 2013/1	Canadian Hematology Quality Improvement Award RK Smiley Research Grant program Prize / Award Canadian Hematology Quality Improvement Award Research Disciplines: Hematology Areas of Research: Hematology Fields of Application: Biomedical Aspects of Human Health
2011/1 - 2011/1	Dr. Harold Frank Award, McGill Medicine McGill University Health Centre Prize / Award Dr. Harold Frank Award, McGill Medicine

User Profile

Researcher Status: Researcher

Research Interests: Immunotherapy/Oncomicrobiome

Research Specialization Keywords: Cancer, Immunotherapy, Microbiome

Disciplines Trained In: Immunology, Oncology

Research Disciplines: Immunology, Oncology

Areas of Research: Host-Tumour Interaction

Fields of Application: Biomedical Aspects of Human Health

Employment

2022/6	Associate Professor Medicine, Medicine, CHUM - Université de Montréal Full-time Tenure Status: Tenure
2018/1 - 2022/5	Assistant Professor Medicine, Medicine, CHUM - Université de Montréal Full-time, Assistant Professor Tenure Status: Tenure

Affiliations

The primary affiliation is denoted by (*)

(*) 2022/6	Associate Professor, Medicine, Division of Hemato-Oncology, CHUM - Université de Montréal
2018/1	Principal Investigator, Cancer Axis, CRCHUM
2018/1 - 2022/5	Assistant Professor Medicine, Université de Montréal, Division of Hemato-Oncology, CHUM Assistant Professor Medicine
2015/9 - 2017/9	Guest Lecturer, Department of Immunology, Université de Paris VI (P & M Curie) Guest Lecturer
2014/11 - 2017/9	Teaching Assistant, Department of Immunology, Université de Paris XI (Paris-Sud) Teaching Assistant
2014/10 - 2017/9	PhD Student, Research, Institut Gustave-Roussy
2012/9 - 2014/10	Resident,, Hematology, University of Toronto
2014/9 - 2014/9	Locum Physician, Medicine, Sault-Saint Marie Hospital Internal Medecine
2009/9 - 2012/9	Resident, Internal Medicine, Medicine, McGill University Resident, Internal Medicine
2005/9 - 2009/7	Medical Student, Medicine, Université de Montréal Medical Student

Research Funding History

Awarded [n=10]

2024/1 - 2027/6 Co-investigator	Canadian Institutes of Health Research (CIHR), Grant Clinical Research Project?: Yes Project Description: Fecal microbiota transplantation in combination with immune checkpoint blockade in patients with advanced melanoma: A randomized phase II trial

Funding Sources:

2024/1 - 2027/6 Canadian Institutes of Health Research (CIHR)
Fecal microbiota transplantation in combination with immune checkpoint blockade in patients with adv
Total Funding - 1,800,000 (Canadian dollar)
Portion of Funding Received - 300,000 (Canadian dollar)
Funding Renewable?: No
Funding Competitive?: Yes

2023/4 - 2027/4 FRQS Junior 2 Ranked #1, Grant
Principal Investigator Clinical Research Project?: No

Funding Sources:

2023/4 - 2027/4 Fonds de recherche du Québec - Santé (FRQS)
Junior 2
Total Funding - 243,230 (Canadian dollar)
Portion of Funding Received - 243,230 (Canadian dollar)
Funding Competitive?: Yes

2024/1 - 2026/12 Canadian Cancer Society, Grant
Principal Investigator Clinical Research Project?: Yes
Project Description: CanBiome2: Phase II randomized trial of fecal microbiome transplantation in combination with immunotherapy in advanced melanoma patients

Funding Sources:

2024/1 - 2026/12 Canadian Cancer Society
CanBiome2: Phase II randomized trial of fecal microbiome transplantation in combination with IO
Total Funding - 1,000,000 (Canadian dollar)
Portion of Funding Received - 300,000 (Canadian dollar)
Funding Competitive?: Yes

2024/1 - 2026/12 Weston Foundation, Grant
Co-investigator Clinical Research Project?: No
Project Description: CanBiome2: Phase II randomized trial of fecalmicrobiome transplantation in combination with immunotherapy in advancedmelanoma patients

Funding Sources:

2024/1 - 2026/12 W. Garfield Weston Foundation
CanBiome2: Phase II randomized trial of fecal microbiome transplantation in combination with IO
Total Funding - 1,000,000 (Canadian dollar)
Portion of Funding Received - 700,000 (Canadian dollar)
Funding Competitive?: Yes

2024/6 - 2026/6 Guy Lafleur CHUM fondation, Grant
Principal Investigator Clinical Research Project?: No

Funding Sources:

2024/6 - 2026/6 Fondation du Centre Hospitalier de l'Université de Montréal (CHUM)
Role of fungal mycobiome in lung cancer.
Total Funding - 250,000 (Canadian dollar)
Portion of Funding Received - 250,000 (Canadian dollar)
Funding Competitive?: Yes

2023/1 - 2026/1 Terry Fox Research Institute Young investigator award: Impact of diet on response to cancer immunotherapy., Grant
Principal Investigator

Clinical Research Project?: No

Funding Sources:

2023/1 - 2026/1 Terry Fox Research Institute (TFRI)
Young investigator
Total Funding - 225,000 (Canadian dollar)
Portion of Funding Received - 225,000 (Canadian dollar)
Funding Competitive?: Yes

2023/10 - 2025/12
Principal Investigator

Axelys Quebec Government, Grant
Clinical Research Project?: Yes
Project Description: Castalagin,a prebiotic to increase the effectiveness of cancer immunotherapy

Funding Sources:

2024/1 - 2026/1 Ministère des Services gouvernementaux (MSG) (Québec)
Castalagin, a prebiotic to increase the effectiveness of cancer immunotherapy
Total Funding - 700,000 (Canadian dollar)
Portion of Funding Received - 400,000 (Canadian dollar)
Funding Competitive?: Yes

2020/9 - 2025/8
Co-applicant

Candian Insitutes of Health Reasearch (CIHR), Grant, Operating
Clinical Research Project?: No
Project Description: Prebiotics for cancer immunotherapy

Funding Sources:

2020/9 - 2024/8 Canadian Institutes of Health Research (CIHR)
CIHR Spring 2020
Total Funding - 935,000 (Canadian dollar)
Portion of Funding Received - 50,000 (Canadian dollar)
Funding Competitive?: Yes

2022/7 - 2025/7
Principal Applicant

Terry Fox Research Institute - Clinician scientist: Study the various microbiomes in NSCLC., Grant
Clinical Research Project?: No

Funding Sources:

2022/5 - 2025/4 Terry Fox Research Institute (TFRI)
TFRI-MOHCCN-MCC
Total Funding - 225,000 (Canadian dollar)
Portion of Funding Received - 75,000 (Canadian dollar)
Funding Competitive?: Yes

2019/12 - 2025/1
Co-investigator

Horizon 2020-EUROPEAN COMMISSION, Grant
Clinical Research Project?: No
Project Description: Exploiting research outcomes and applicationpotential of the human microbiome for personalised prediction, prevention andtreatment of disease

Funding Sources:

2020/1 - 2030/1 Horizon 2020-European commission
Horizon 2020 – The Framework Programme for Research and Innovation
Total Funding - 23,000,000 (Canadian dollar)
Portion of Funding Received - 1,400,000 (Canadian dollar)
Funding Renewable?: No
Funding Competitive?: Yes

Completed [n=27]

2020/1 - 2024/12
Principal Applicant

Canadian cancer society - Impact Grant: Phase I FMT clinical trial., Grant, Operating
Clinical Research Project?: Yes
Project Description: Phase two clinical trial

Funding Sources:

2020/1 - 2024/12 Canadian Cancer Society
IMPACT
Total Funding - 1,500,000 (Canadian dollar)
Portion of Funding Received - 600,000 (Canadian dollar)
Funding Renewable?: No
Funding Competitive?: Yes

2019/10 - 2024/9
Principal Investigator

Canadian Institutes of Health Research (CIHR), Grant
Clinical Research Project?: No

Funding Sources:

2019/10 - 2024/9 Canadian Institutes of Health Research (CIHR)
Projet bourse d'Automne 2019
Total Funding - 760,000 (Canadian dollar)
Portion of Funding Received - 760,000 (Canadian dollar)
Funding Competitive?: Yes

2023/6 - 2024/6
Principal Applicant

Seerave Foundation Grant, Grant
Clinical Research Project?: No
Project Description: Impact of castalagin prebiotic on the gut microbiota and immune response to anti-PD-1 therapy

Funding Sources:

2022/6 - 2024/5 3R Research Foundation (Switzerland)
Seerave Foundation
Total Funding - 200,000 (Canadian dollar)
Portion of Funding Received - 100,000 (Canadian dollar)
Funding Competitive?: Yes

2021/6 - 2024/5
Principal Applicant

Weston Foundation: Clinical trial Camu-Camu, Grant
Clinical Research Project?: Yes

Funding Sources:

2021/6 - 2024/5 Weston Foundation
The Weston Family
Total Funding - 1,000,000 (Canadian dollar)
Portion of Funding Received - 700,000 (Canadian dollar)
Funding Competitive?: Yes

2020/1 - 2022/12
Principal Applicant

Real world evidence of non small cell lung cancer - Astrazeneca, Grant
Clinical Research Project?: No
Project Description: Prospective real world evidence of non small cell lung cancer patients on immunotherapy.

Funding Sources:

2020/1 - 2022/12 Astrazeneca
Astrazeneca reaserch grant
Total Funding - 175,000 (Canadian dollar)
Portion of Funding Received - 80,000 (Canadian dollar)
Funding Renewable?: No
Funding Competitive?: Yes

2020/1 - 2022/12 MedTeq Imagia, Grant
Principal Applicant Clinical Research Project?: No

Funding Sources:

2020/1 - 2022/12 MedTeq Imagia
Radiomic biomarkers in the treatment of cancer by immunotherapy
Total Funding - 650,000 (Canadian dollar)
Portion of Funding Received - 373,000 (Canadian dollar)
Funding Competitive?: Yes

2020/1 - 2022/12 Département de la défense MGS DoD, Grant
Co-applicant Clinical Research Project?: Yes

Funding Sources:

2020/1 - 2022/12 Département de la défense MGS DoD
Manipulate the gut microbiota to enhance immune checkpoint inhibitors response in bladder cancer
Total Funding - 400,000 (Canadian dollar)
Portion of Funding Received - 50,000 (Canadian dollar)
Funding Competitive?: Yes

2020/1 - 2022/1 Merck, Grant
Principal Applicant Clinical Research Project?: Yes

Funding Sources:

2020/1 - 2022/1 Merck
Biobank of tissues, blood and clinical data: primary cancers and lung metastases
Total Funding - 20,000 (Canadian dollar)
Portion of Funding Received - 20,000 (Canadian dollar)
Funding Competitive?: Yes

2021/1 - 2022/1 Kaleido Biosciences: Understand the role of fiber in diet., Grant
Principal Applicant Clinical Research Project?: Yes

Funding Sources:

2021/1 - 2023/1 Kaleido Biosciences
Caractérisation des composés métaboliques du microbiome: réponse à l'immunothérapie en NSCLC
Total Funding - 87,000 (Canadian dollar)
Portion of Funding Received - 87,000 (Canadian dollar)
Funding Competitive?: Yes

2018/1 - 2021/12 Institut du cancer de Montréal (ICM) - Biobanque cancer du poumon, Grant
Principal Applicant Clinical Research Project?: No

Funding Sources:

2018/1 - 2021/12 Institut du Cancer de Montréal
Biobanque poumon
Total Funding - 240,000 (Canadian dollar)
Portion of Funding Received - 240,000 (Canadian dollar)
Funding Competitive?: Yes

2021/1 - 2021/12
Principal Applicant
BMS, Grant
Clinical Research Project?: No

Funding Sources:

2021/1 - 2021/12 Bristol-Myers Squibb Canada Inc.
Ipilimumab plus nivolumab dans le mésothéliome pleural malin non résécable (MPM): Real world Data
Total Funding - 25,000 (Canadian dollar)
Portion of Funding Received - 25,000 (Canadian dollar)
Funding Competitive?: Yes

2018/7 - 2021/8
Principal Investigator
Institut du cancer de Montréal (ICM) (équipement Germ-free/Gnotobiotique; plateforme de Culturomique pour unité. En Microbiome), Grant
Clinical Research Project?: No

Funding Sources:

2018/7 - 2021/8 Cancer Institute of Montreal
équipement Germ-free/Gnotobiotique; plateforme de Culturomique
Total Funding - 355,000 (Canadian dollar)
Portion of Funding Received - 355,000 (Canadian dollar)
Funding Competitive?: Yes

2019/7 - 2021/7
Co-investigator
Onco-Tech, Grant
Clinical Research Project?: No
Project Description: Multiomics biomarkers of response for immune checkpointinhibitors

Funding Sources:

2019/7 - 2021/7 Fonds de la Recherche en Santé du Québec (FRSQ)
Onco-Tech
Total Funding - 350,000 (Canadian dollar)
Portion of Funding Received - 200,000 (Canadian dollar)
Funding Competitive?: Yes

2018/7 - 2021/6
Principal Applicant
The microbiota : a novel tool to prevent cancer and boost anti-cancer immunotherapy. 1. Germ-free/Gnotobiotic equipment; 2. Culturomic platform equipment, Grant, Equipment
Clinical Research Project?: No

Funding Sources:

2018/7 - 2021/6 Montreal cancer Institute
Microbiome unit
Total Funding - 355,000 (Canadian dollar)
Portion of Funding Received - 355,000 (Canadian dollar)
Funding Competitive?: Yes

2018/1 - 2021/1
Principal Applicant
Brain Gain initiative of the Montreal cancer Institute, Research Chair
Clinical Research Project?: No
Project Description: Lung cancer and microbiota interactions forimmunotherapy efficacy and refractory patients
Research Uptake: Lung cancer and microbiota interactions forimmunotherapy efficacy and refractory patients

Funding Sources:

2018/1 - 2021/1
Institut du cancer de Montréal
Institut du cancer de Montréal
Total Funding - 225,000 (Canadian dollar)
Portion of Funding Received - 50,000 (Canadian dollar)
Funding Renewable?: Yes
Funding Competitive?: Yes

2018/1 - 2021/1
Principal Applicant
CRCHUM research funding, Research Chair
Clinical Research Project?: No
Project Description: Influence of salivary and gut microbiota in response to anti-PD-1 mAb inmetastatic renal cell carcinoma
Research Uptake: Influence of salivary and gut microbiota in response to anti-PD-1 mAb in metastatic renal cell carcinoma

Funding Sources:

2018/1 - 2021/1
Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM)
Centre de recherche du centre hospitalier de l'université de Montréal (CRCHUM)
Total Funding - 250,000 (Canadian dollar)
Portion of Funding Received - 50,000 (Canadian dollar)
Funding Renewable?: Yes
Funding Competitive?: Yes

2020/1 - 2021/1
Principal Applicant
Da Volterra, Grant
Clinical Research Project?: No

Funding Sources:

2020/1 - 2021/1
Da Volterra
Determine the efficacy of DAV131 in mice treated with antibiotics and ICI
Total Funding - 480,000 (Canadian dollar)
Portion of Funding Received - 480,000 (Canadian dollar)
Funding Competitive?: Yes

2020/1 - 2021/1
Principal Applicant
Vedanta Biosciences, Grant
Clinical Research Project?: No

Funding Sources:

2020/1 - 2021/1
Vedanta Biosciences
The role of the intestinal microbiome in the treatment of different cancers
Total Funding - 87,000 (Canadian dollar)
Portion of Funding Received - 87,000 (Canadian dollar)
Funding Competitive?: Yes

2020/1 - 2021/1
Co-applicant
Réseau de thérapie cellulaire, tissulaire et génique du Québec (ThéCell), Grant
Clinical Research Project?: No

Funding Sources:

2020/1 - 2021/1 Réseau de thérapie cellulaire, tissulaire et génique du Québec (ThéCell)
TheCell
Total Funding - 30,000 (Canadian dollar)
Portion of Funding Received - 10,000 (Canadian dollar)
Funding Competitive?: Yes

2019/12 - 2020/12
Principal Applicant
Fondation du CHUM – Famille Préfontaine, Grant
Clinical Research Project?: No

Funding Sources:

2019/12 - 2020/12 Fondation du CHUM – Famille Préfontaine
Le microbiome intestinal et l'immunothérapie
Total Funding - 151,000 (Canadian dollar)
Portion of Funding Received - 151,000 (Canadian dollar)
Funding Competitive?: Yes

2019/1 - 2020/12
Co-applicant
Étude clinique en oncologie Hudson, Grant
Clinical Research Project?: Yes

Funding Sources:

2019/1 - 2020/12 AstraZeneca Canada Inc.
Étude clinique en oncologie Hudson
Total Funding - 46,665 (Canadian dollar)
Portion of Funding Received - 46,665 (Canadian dollar)
Funding Competitive?: Yes

2020/1 - 2020/12
Principal Applicant
CFI funding for MALDITOF mass spectrometer, Grant, Equipment
Clinical Research Project?: No
Project Description: Acquisition of MALDITOF mass spectrometer for Culturomics

Funding Sources:

2020/1 - 2020/12 CFI
CFI
Total Funding - 250,000 (Canadian dollar)
Portion of Funding Received - 250,000 (Canadian dollar)
Funding Renewable?: No
Funding Competitive?: Yes

2018/8 - 2020/9
Principal Applicant
AstraZeneca- Lung cancer Registry, Grant
Clinical Research Project?: Yes

Funding Sources:

2018/7 - 2020/6 AstraZeneca
Lung cancer biobank
Total Funding - 20,000 (Canadian dollar)
Portion of Funding Received - 10,000 (Canadian dollar)
Funding Competitive?: Yes

2020/1 - 2020/1
Principal Investigator
Fondation canadienne pour l'innovation (FCI), Grant
Clinical Research Project?: No

Funding Sources:

2020/1 - 2020/1
Canadian Innovation Centre
Fond d'innovation
Total Funding - 250,000 (Canadian dollar)
Portion of Funding Received - 250,000 (Canadian dollar)
Funding Competitive?: Yes

2019/1 - 2020/1
Principal Investigator

Imagia funding, Grant
Clinical Research Project?: No
Project Description: Replacing radiologistswith artificial intelligence: Predicting the response to cancerimmunotherapy

Funding Sources:

2019/1 - 2020/1
Imagia
Replacing radiologists with artificial intelligence: Predicting the response to cancer immunotherapy
Total Funding - 15,000 (Canadian dollar)
Portion of Funding Received - 15,000 (Canadian dollar)
Funding Renewable?: No
Funding Competitive?: Yes

2018/4 - 2019/4
Principal Applicant

ThéCell, Grant
Clinical Research Project?: No
Project Description: T lymphocytes cross-reactivitybetween the gut microbiota and lung cancer

Funding Sources:

2018/4 - 2019/4
ThéCell
ThéCell
Total Funding - 30,000 (Canadian dollar)
Portion of Funding Received - 30,000 (Canadian dollar)
Funding Competitive?: Yes

2018/3 - 2019/2
Principal Applicant

KCRNC-KCC-CUASF grant: Define the importance of microbiome in renal cell carcinoma., Grant, Establishment
Clinical Research Project?: Yes
Project Description: Immune-potentiating impact of the gut microbiomeon kidney cancer infiltrate: a novel predictor of immune checkpoint inhibitorsresponse
Research Uptake: Immune-potentiating impact of the gut microbiomeon kidney cancer infiltrate: a novel predictor of immune checkpoint inhibitorsresponse

Funding Sources:

2018/3 - 2018/3
KCRNC-KCC-CUASF
KCRNC-KCC-CUASF
Total Funding - 50,000 (Canadian dollar)
Portion of Funding Received - 50,000 (Canadian dollar)
Funding Renewable?: No
Funding Competitive?: Yes

Declined [n=1]

2021/7 - 2026/6
Principal Applicant

Canadian Research Chair Tier 2 - refused because impossible to combine CIHR and FRQS. (DECLINED), Research Chair
Clinical Research Project?: No

Funding Sources:

2022/3 - 2027/3	160630 Canada Inc. Canadian Research Chair Tier 2 Total Funding - 600,000 (Canadian dollar) Portion of Funding Received - 1 (Canadian dollar) Funding Competitive?: Yes

Courses Taught

2023/10/11 - 2023/10/11	Guest lecturer, Université de Montréal Course Title: Introduction à l'immunothérapie Guest Lecture?: Yes
2023/03/15 - 2023/03/15	Guest lecturer, Université de Montréal Course Title: Immunothérapie du Cancer
2022/09/09 - 2022/12/16	Guest lecturer, Université de Montréal Course Title: Immunothérapie et Immunologie du Cancer
2022/03/02 - 2022/03/02	Guest lecturer, Université de Montréal Course Title: Oncologie - Médecine Moléculaire
2021/11/26 - 2021/11/26	Guest lecturer, Université de Montréal Course Title: Immunothérapie du cancer
2020/03/10 - 2021/06/10	Internship supervisor, Université de Montréal Course Title: Caractérisation du microbiote intestinal d'un patient avec un mélanome métastatique qui a développé une colite.
2021/03/31 - 2021/03/31	Guest lecturer, McGill University Course Title: Physiology
2020/09/09 - 2020/09/09	Guest lecturer, Université de Montréal Course Title: L'introduction à l'immunothérapie du cancer et ses complications
2019/05/07 - 2019/08/07	Internship supervisor, Université de Montréal Course Title: Implication du microbiote dans la réponse aux traitements à l'anti-PD-1 dans le cancer.
2019/03/20 - 2019/03/20	Guest Lecturer, Université de Montréal Course Title: Immunologie fondamentale
2018/05/08 - 2018/08/08	Internship supervisor, Université de Montréal Course Title: L'implication du microbiote dans l'efficacité de l'immunothérapie dans le cancer
2018/02/02 - 2018/02/02	Seminar speaker, McGill University Course Title: Pharmacology Course Level: Graduate
2017/11/16 - 2017/11/16	Teaching Assistant, Immunology, Université de Paris XI (Paris-Sud) Course Title: Place du microbiote intestinal dans le cancer.
2017/01/02 - 2017/01/02	Teaching Assistant, Immunology, Université de Paris VI (P & M Curie) Course Title: Place du microbiote intestinal dans le cancer. Course Topic: Micobiote and cancer Course Level: College Section: Master 2 d'immunologie

2016/12/05 - 2016/12/06	Teaching Assistant, Immunology, Université de Bourgogne Course Title: Immunité des muqueuses Course Topic: micobiote and cancer Course Level: College Section: Immunité des muqueuses
2016/12/01 - 2016/12/01	Teaching Assistant, Immunology, Université de Paris XI (Paris-Sud) Course Title: Place du microbiote intestinal dans le cancer. Course Topic: Micobiote and cancer Course Level: College Section: Cours aux étudiants de Master 2 d'immunologie
2016/11/02 - 2016/11/02	Teaching Assistant, Immunology, Université de Paris XI (Paris-Sud) Course Title: Place du microbiote dans la greffe aujourd'hui. Course Level: College Section: Cours faculté de medicine du KB. Étudiant master 2 greffe Academic Session: Winter
2015/12/01 - 2015/12/01	Teaching Assistant, Immunology, Université de Paris XI (Paris-Sud) Course Title: Le rôle des Treg dans le cancer. Course Level: College Section: Cours aux étudiants de Master 2 d'immunologie Academic Session: Winter
2015/12/01 - 2015/12/01	Teaching Assistant, Immunology, Université de Paris XI (Paris-Sud) Course Title: Place du microbiote intestinal dans le cancer. Course Level: College Section: Cours aux étudiants de Master 2 d'immunologie Academic Session: Winter

Student/Postdoctoral Supervision

Bachelor's [n=6]

2022/1 - 2022/5 Principal Supervisor	Yasmine Yesli (Completed) , Université de Montréal Student Degree Start Date: 2021/9 Student Degree Received Date: 2022/3 Thesis/Project Title: Implication du microbiote intestinal et modifications immunologiques chez des patients atteints de mélanome avancé traités par immunothérapie et greffe fécale. Present Position: student
2021/9 - 2021/12 Principal Supervisor	Célia Griveau (Completed) , Université de Montréal Student Degree Start Date: 2021/1 Student Degree Received Date: 2021/6 Thesis/Project Title: Comprendre les modifications du microbiote intestinal chez les patients traités par greffe fécale en oncologie Present Position: student
2020/9 - 2020/12 Principal Supervisor	Melodie Boko (Completed) , Universite de Montreal Student Degree Start Date: 2020/9 Student Degree Received Date: 2021/9 Student Canadian Residency Status: Canadian Citizen Thesis/Project Title: Link between gut microbiome and immunotherapy response in cancer Present Position: Student

2019/9 - 2020/4
Principal Supervisor
Julien Bertrand (Completed) , Université de Montreal
Student Degree Start Date: 2019/9
Student Degree Received Date: 2020/3
Thesis/Project Title: Microbiome and cancer
Present Position: Bachelor’s

2018/8 - 2019/8
Principal Supervisor
Manuela Henry (Completed) , McGill university
Student Degree Start Date: 2019/1
Student Degree Received Date: 2019/6
Thesis/Project Title: Gut Microbiota as a Novel Predictor of Immune Checkpoint Inhibitors Response in non-small cell lung cancer
Present Position: Student at McGill University Department Of Microbiology And Immunology

2018/5 - 2018/8
Principal Supervisor
David Frizon-Peresa (Completed) , Montreal university
Student Degree Start Date: 2018/4
Student Degree Received Date: 2019/3
Thesis/Project Title: Gut Microbiota as a Novel Predictor of Immune Checkpoint Inhibitors Response in non-small cell lung cancer
Present Position: Student at Montreal University Department Of Microbiology

Master’s Thesis [n=6]

2023/4 - 2023/9
Principal Supervisor
Clara Sehl (Completed) , Universite de Montreal
Student Degree Start Date: 2020/9
Student Degree Received Date: 2023/9
Thesis/Project Title: Leaky Gut, a key factor in the response and clinical course of patients with metastatic melanoma or lung cancer treated with the combination of immunotherapy and faecal microbiome transfer
Present Position: Master’s Thesis

2022/5 - 2023/5
Co-Supervisor
Cecilia Hermosillia Samayoa (Completed) , CRCHUM
Student Degree Start Date: 2022/6
Student Degree Received Date: 2023/5
Thesis/Project Title: Bioinformatic analysis of the immunotherapy repossess in cancer patients.
Present Position: Student

2021/10 - 2022/10
Principal Supervisor
Marion Tonneau (Completed) , CRCHUM
Student Degree Start Date: 2020/9
Student Degree Received Date: 2022/8
Thesis/Project Title: Impact of the microbiome in cancer patients treated with radiotherapy.
Present Position: Doctorate

2020/1 - 2020/3
Principal Supervisor
Iris Mimpen (Completed) , Amsterdam university
Student Degree Start Date: 2020/1
Student Degree Received Date: 2020/7
Student Canadian Residency Status: Study Permit
Thesis/Project Title: Gut microbiota shift during anti-PD-1 treatment
Present Position: Student

2020/1 - 2022/9
Principal Supervisor
Antoine Desîlets (Completed) , Universite de Montreal
Student Degree Start Date: 2020/1
Student Degree Received Date: 2022/9
Student Canadian Residency Status: Canadian Citizen
Thesis/Project Title: Efficacy of immunotherapy in patient with NSCLC
Present Position: Resident

2020/1 - 2020/7
Principal Supervisor
Myriam Benlaïfaoui (Completed) , Universite de Montreal
Student Degree Start Date: 2019/9
Student Degree Received Date: 2020/7
Thesis/Project Title: Link between gut microbiome and immunotherapy response in cancer patients.
Present Position: Phd student

Doctorate [n=4]

2023/6
Principal Supervisor
Yongjia Hu (In Progress) , Universite de Montreal
Student Degree Start Date: 2023/6
Thesis/Project Title: Impactof the local lung microbiome on the efficacy of the immunotherapy in lungcancer
Present Position: PhD student

2023/2
Principal Supervisor
Sreya Duttagupta (In Progress) , Université de Montréal
Student Degree Start Date: 2023/2
Student Degree Expected Date: 2027/2
Student Canadian Residency Status: Study Permit
Thesis/Project Title: Unraveling the mechanism of bacterialcomptabilities between donors and recipients in fecal microbiotatransplantation clinical trials in oncology
Present Position: PhD student

2023/1
Principal Supervisor
Jade Maillou (In Progress) , Université de Montréal
Student Degree Start Date: 2023/1
Student Degree Expected Date: 2027/1
Thesis/Project Title: Impact du polyphénol castalagin sur la composition dumicrobiome intestinal dans la réponse aux immunothérapies du cancer
Present Position: PhD Student

2020/9 - 2024/9
Principal Supervisor
Myriam Benlaïfaoui (In Progress) , Universite de Montreal
Student Degree Start Date: 2020/9
Student Degree Expected Date: 2024/10
Student Canadian Residency Status: Study Permit
Thesis/Project Title: Link between gut microbiome and immunotherapy response in cancer patients. Completed Pre-doc jun 2022
Project Description: Link between gut microbiome and immunotherapy response in cancer patients
Present Position: PhD student

Post-doctorate [n=5]

2024/3
Principal Supervisor
Babacar Mbaye (In Progress) , CRCHUM
Student Degree Start Date: 2024/3
Thesis/Project Title: To determine the importance of the mycobiome and its interaction with commensal bacteria in lung cancer patients treated with immunotherapy.
Present Position: Post-doctorate

2022/9 - 2024/9
Principal Supervisor
Eder Salazar (In Progress) , CRCHUM
Student Degree Start Date: 2022/9
Thesis/Project Title: Bioinformatician
Present Position: Post-doctorate

2019/11 - 2021/6
Principal Supervisor
Corentin Richard (Completed) , CRCHUM
Student Degree Start Date: 2019/10
Student Degree Received Date: 2022/6
Thesis/Project Title: Bioinformatic analysis of the gut microbiota
Present Position: Post-doctorate

2019/8 - 2023/8
Principal Supervisor
Khoudia Diop (Completed) , CRCHUM
Student Degree Start Date: 2019/8
Student Degree Received Date: 2023/7
Thesis/Project Title: Coupling culturomics and metagenomics in patients amenable to immunothrapy
Present Position: Postdoc

2018/1 - 2023/1
Principal Supervisor
Meriem Messaoudene (Completed) , CRCHUM
Student Degree Start Date: 2018/1
Student Degree Received Date: 2022/1
Thesis/Project Title: Identification of a prebiotics to increase immunotherapy efficacy
Present Position: Post-doctorate

Diploma [n=7]

2023/6
Principal Supervisor
Olivier Salko (In Progress) , Université de Montréal
Student Degree Start Date: 2023/1
Thesis/Project Title: The importance of the microbiome in patients with lung cancer treated with neoadjuvant.
Present Position: Clinician researcher

2023/4 - 2024/4
Principal Supervisor
Taiki Hakozaki (In Progress) , Universite de Montreal
Student Degree Start Date: 2023/4
Student Degree Expected Date: 2024/4
Thesis/Project Title: Development of biomarkers for advanced cancer utilizing genomic analysis of gut microbiota

2022/9 - 2023/9
Principal Supervisor
Marina De Figueiredo (Completed) , Universite de Montreal
Student Degree Start Date: 2022/9
Student Degree Received Date: 2023/9
Thesis/Project Title: Fecal microbiota transplatation in combination with anti-PD-1 for patients with metastatic melanoma.

2021/9 - 2022/9
Principal Supervisor
Edouard Auclin (Completed) , CRCHUM
Student Degree Start Date: 2021/9
Student Degree Received Date: 2022/9
Thesis/Project Title: Fecal microbiome transplantation Clinical trial (MIMICS and FMT Luminate)
Present Position: Fellow

2019/8
Principal Supervisor
Xavier Deschenes (Completed) , Université de Montréal
Student Degree Start Date: 2019/8
Thesis/Project Title: Thrombose et cancer du poumon sous immunothérapie.

2018/9 - 2022/9
Principal Supervisor
Lena Cvetkovic (Completed) , Université de Montréal
Student Degree Start Date: 2018/9
Student Degree Received Date: 2022/9

2018/1 - 2020/1
Principal Supervisor
Arielle Elkrief (Completed) , McGill university
Student Degree Start Date: 2018/9
Student Degree Received Date: 2020/9
Thesis/Project Title: Gut Microbiota as a Novel Predictor of Immune Checkpoint Inhibitors Response in non-small cell lung cancer
Present Position: Oncology Fellow

Habilitation [n=2]

2020/9 - 2020/10
Principal Supervisor
Laurence Dubé (Completed) , Universite de Montreal
Student Degree Start Date: 2020/9
Student Canadian Residency Status: Canadian Citizen
Thesis/Project Title: Link between gut microbiome and immunotherapy response in cancer
Present Position: Student

2020/1 - 2021/7
Principal Supervisor
Omar El Ouarzadi (Completed) , Universite de Montreal
Student Degree Start Date: 2020/9
Student Canadian Residency Status: Canadian Citizen
Thesis/Project Title: Link between gut microbiome and immunotherapy response in cancer
Present Position: Student

Staff Supervision

Journal Review Activities

Peer Reviewer,Cancer Cell
Number of Works Reviewed / Refereed: 4

Peer Reviewer,Nature Review Clinical Oncology
Number of Works Reviewed / Refereed: 1

Peer reviewer,Nature Journal
Number of Works Reviewed / Refereed: 1

Peer Reviewer,Cancer Discovery
Number of Works Reviewed / Refereed: 2

Peer Reviewer,Nature Immunology
Number of Works Reviewed / Refereed: 2

Peer Reviewer,Gut
Number of Works Reviewed / Refereed: 12

Peer Reviewer,Nature Review Immunology
Number of Works Reviewed / Refereed: 1

Peer Reviewer,Clinical Cancer Research
Number of Works Reviewed / Refereed: 1

Peer reviewer,Nature Review Cancer
Number of Works Reviewed / Refereed: 1

Peer Reviewer,Nature Cancer
Number of Works Reviewed / Refereed: 3

Peer Reviewer,Nature Metabolism
Number of Works Reviewed / Refereed: 1

Peer reviewer,Journal of Clinical Oncology
Number of Works Reviewed / Refereed: 1

Peer Reviewer,Nature Biomedical Engineering
Number of Works Reviewed / Refereed: 1

Peer Reviewer,Nature Communications
Number of Works Reviewed / Refereed: 2

Peer reviewer,Clinical Microbiome
Number of Works Reviewed / Refereed: 1

Peer reviewer,Nature Reviews
Number of Works Reviewed / Refereed: 3

Peer Reviewer,European Journal of Cancer
Number of Works Reviewed / Refereed: 1

Peer reviewer,Cell Report Medecine
Number of Works Reviewed / Refereed: 1

Peer Reviewer,Microbiome
Number of Works Reviewed / Refereed: 1

Peer reviewer,Clinical Cancer Research
Number of Works Reviewed / Refereed: 1

Peer Reviewer,PNAS
Number of Works Reviewed / Refereed: 2

Peer reviewer,British Journal of Cancer
Number of Works Reviewed / Refereed: 2

Peer Reviewer,Current Oncology
Number of Works Reviewed / Refereed: 2

Peer Reviewer,Nature Medicine
Number of Works Reviewed / Refereed: 10

2024/1 - 2024/1 Peer Reviewer,Nature Computational Science
Number of Works Reviewed / Refereed: 1

2018/3 - 2018/12 Peer Reviewer,European Urology
Number of Works Reviewed / Refereed: 2

2017/1 - 2017/12 Peer Reviewer,Canadian Journal of surgery
Number of Works Reviewed / Refereed: 3

2016/1 - 2017/12 Peer Reviewer,OncoImmunology
Number of Works Reviewed / Refereed: 31

2016/1 - 2017/12 Peer Reviewer,Thoracic Cancer
Number of Works Reviewed / Refereed: 1

2016/1 - 2017/10 Peer Reviewer,Cancer Research
Number of Works Reviewed / Refereed: 1

Graduate Examination Activities

2021/9 - 2021/9 Thesis Defense Examiner, Université Laval

2019/2 - 2019/2 Master's Proposal Defense Member, Université de Montréal

Research Funding Application Assessment Activities

2022/1 - 2022/1 External Reviewer, Comité des évaluateurs de bourse maîtrise 2022-2023, Organization, Non-academic Reviewer, Fonds de recherche du Québec - Santé (FRQS)

Other Memberships

2021/4 - 2023/4 Associate Member, American Society of Clinical Oncology

2017/9 - 2022/11 Associate Member, American Association for Cancer Research
Associate Member

2018/2 - 2019/1 Associate member, ThéCell (Réseau de thérapie cellulaire et tissulaire du Québec)
Associate member

2012/1 - 2017/10 Associate Member, Canadian Hematology Society
Associate Member

2012/1 - 2017/10 Associate Member, American Society of Hematology
Associate Member

Presentations

1. (2024). Lung Microbiome and improving the gut microbiome composition to increase immunotherapy response.Prevalung, Paris, France
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes
2. (2024). Microbiome and cancer. DU Thérapeutiques Immunologiques, Université de Paris-Cite, Paris, France
Main Audience: Knowledge User
Invited?: Yes, Keynote?: Yes
3. (2024). Comment votre santé intestinale peut affecter le traitement de votre cancer du sang et votre qualité de vie. Société de Leucémie et Lymphome du Canada LLSC, Montréal, Canada
Main Audience: Knowledge User
Invited?: Yes
4. (2024). ONCOBIOME General Assembly, Sweden
Main Audience: Knowledge User
Invited?: Yes, Keynote?: Yes
5. (2024). Le cancer du poumon en 2024 et plus.Hôpital de Chicoutimi, Chicoutimi, Canada
Main Audience: Knowledge User
Invited?: Yes
6. (2024). Should you profile the gut microbiome of your patients with NSCLC?. Canadian Lung Cancer Conference CCLC, Vancouver, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes
7. (2024). DAVA's 2024 Summit on Thoracic Malignancies, United States of America
Main Audience: Knowledge User
Invited?: Yes, Keynote?: Yes

8. (2024). Clinical traials portfolio.CHUM Médecins oncologues meeting, Montréal, Canada
   Main Audience: Knowledge User
   Invited?: Yes, Keynote?: Yes
9. (2024). Challenges to implement microbiome in clinical trials.European Lung Cancer Congress ELCC/ ESMO, Prague, Czechia
   Main Audience: Knowledge User
   Invited?: Yes, Keynote?: Yes
10. (2024). The Gut Microbiome from a Biomarker to Novel Therapeutic Avenue in NSCLC.Immunotherapy Working Group (IWG), T Fox Chase Cancer Center, Pensylvania, United States of America
    Main Audience: Knowledge User
    Invited?: Yes
11. (2024). Novel Biomarkers of Cancer Immunotherapy from Gut to Lung Microbiome.TFRI's 10th Scientific Meeting, Toronto, Canada
    Main Audience: Researcher
    Invited?: Yes
12. (2024). How the microbiome affects immunotherapy. European Society For Medical Oncology ESMO, Spain
    Main Audience: Knowledge User
    Invited?: Yes, Keynote?: Yes
13. (2024). Rapide emergence of the gut Micribiome in cancer immunotherapy.ISA Meeting BMS, Brussels, Belgium
    Main Audience: Researcher
    Invited?: Yes, Keynote?: Yes
14. (2024). Prise en charge des patients avec un cancer du poumon localement avancé.Association des médecins Hématologue et Oncologue du Québec AMHOQ, Québec city, Canada
    Main Audience: Knowledge User
    Invited?: Yes
15. (2024). Joe Doupe Young Investigator Award.The international Congress on Academic Medicine ICAM/ AFMC, Vancouver, Canada
    Main Audience: Knowledge User
    Invited?: Yes
16. (2024). How your gut health can improve your blood cancer treatment and quality of life.Société de Leucémie et Lymphome du Canada LLSC, Montréal, Canada
    Main Audience: Knowledge User
    Invited?: Yes
17. (2023). The importance of genomics in immuno-oncologiy. RQDM Les Rendez-vous Génome Québec., Montréal, Canada
    Main Audience: Researcher
    Invited?: Yes, Keynote?: Yes
18. (2023). Gut microbiome in the immuno-oncology arena.the 6th Conference of the Joint International Research Unit on Chemical and Biomolecular Studies on the Microbiome and its Impact on Metabolic Health and Nutrition, Québec, Canada
    Main Audience: Researcher
    Invited?: Yes, Keynote?: Yes
19. (2023). The importance of genomique in immuno-oncology.IUCPQ, Québec, Canada
    Main Audience: General Public
    Invited?: Yes, Keynote?: No

20. (2023). Gut Microbiome: Second Paradigm Shift in Immuno-Oncology.POET Precision Oncology Congress., Calgary, Canada
Main Audience: General Public
Invited?: Yes, Keynote?: Yes

21. (2023). Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma.ESCMID European Society of Clinical Microbiology and Infectious Diseases, Zurich, Switzerland
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes

22. (2023). The Gut Microbiome for Precision Oncology.CCRC Canadian Cancer Research Conference, Halifax, Canada
Main Audience: General Public
Invited?: Yes, Keynote?: Yes

23. (2023). Oncomicrobiome Meeting. Institut Gustave Roussy, Paris, France
Main Audience: General Public
Invited?: Yes, Keynote?: No

24. (2023). Evolution of lung cancer treatments (Poste ESMO).Rencontre des oncologues du Québec., Montréal, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes

25. (2023). Advances in immunotherapy in the treatment of lung and melanoma cancer.Conférence aux médecins du Québec, Montréal, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes

26. (2023). Therapeutics modalities session - Nutritional Intervertions. Melanoma Research Alliance & Seerave Foundation, Microbiome Melanoma Workshop 2023, washingtom D.C, United States of America
Main Audience: General Public
Invited?: Yes, Keynote?: No

27. (2023). The Evolving Paradigms in the Treatment of Resectable Non-Small Cell Lung Cancer.Conférence aux médecins du Québec, Montréal, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes

28. (2023). Update in FMT results.Annual Oncobiome meeting, Munich, Germany
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes

29. (2023). The revolution of the gut microbiome in oncology.IDIGH Infection and Immunity seminar Series, McGill University Health Center, Montréal, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes

30. (2023). Cancer immunotherapy : Mechanisms of Response versus Resistance,. Keystone Symposia, Banff, Canada
Main Audience: General Public
Invited?: Yes, Keynote?: No

31. (2022). Gut microbiome in the immunotherapy arena: from biomarker to therapeutics.Annual Cancer Crosslinks 2022 Oslo, Norway
Main Audience: Researcher
Invited?: Yes, Keynote?: No, Competitive?: Yes

32. (2022). Stratégies to shift microbiota composition and improve immunotherapy efficacy in cancer.The Ottawa Hospital Cancer Center Grand Rounds, Ottawa, Canada
Main Audience: Researcher

33. (2022). Gut microbiome in immuno-oncology: From biomarker to adjuvant therapeutic. AACR2022, United States of America
Main Audience: Researcher
Invited?: Yes, Keynote?: No

34. (2022). From allotransplantation to fecal microbiota transplantation.University of Toronto, Hematology Annual Research Day, Toronto, Canada
Main Audience: Researcher

35. (2022). Diète, microbiome et immunothérapie tous liés contre le cancer.Réseau de recherche en cardiométabolique, diabète et obésité (CMDO), Quebec, Canada
Main Audience: Knowledge User

36. (2022). Microbiote digestif chez les personnes avec cancer ou VIH.Conférence sur invitation, La journée Québécoise du VIH, Montréal, Canada
Main Audience: Researcher

37. (2022). Multi-omics biomarker to predict cancer immunotherapy response. DHDP Scientific RFP 2022, Canada
Main Audience: Researcher
Invited?: Yes, Competitive?: Yes

38. (2022). Diète, microbiome et immunothérapie tous liés contre le cancer.Réseau de recherche en cardiométabolique, diabète et obésité (CMDO) 2022, Canada
Main Audience: Researcher
Invited?: Yes, Competitive?: Yes

39. (2022). Microbiota and Immunity. 6ème Journée scientifique Immunité et Cancer (JSIC), France
Main Audience: Researcher
Invited?: Yes, Competitive?: Yes

40. (2021). Gut microbiome to predict cancer immunotherapy response and toxicity and improve treatment efficacy. Seminar at Albert Einstein College of Medicine, United States of America
Main Audience: Researcher
Invited?: Yes, Keynote?: No, Competitive?: Yes

41. (2021). Durvalumab chez les CPNPC de stade III inopérables: données de vraie vie canadiennes.Hôpital Honoré-Mercier, Saint-Hyacinthe, Canada
Main Audience: Researcher
Invited?: Yes, Competitive?: Yes

42. (2021). L’impact de la composition du microbiote intestinal sur l’efficacité des immunobloquants (PD-L1) en cancer du poumon non à petites cellules.Poumon Québec, Soirée scientifique en cancer du poumon, Canada
Main Audience: Knowledge User
Invited?: Yes, Competitive?: Yes

43. (2021). La prise en charge du COVID-19 dans les unités d’oncologie.Réunion scientifique multicentrique (Charles-Le Moyne, Sacré Cœur, CHUM, CUSM), Canada
Main Audience: Researcher
Invited?: Yes, Competitive?: Yes

44. (2021). Présentation des données RWE de PACIFIC (local et de l’Europe)/données majeures de l’ESMO. Astrazeneca Conference, France
Main Audience: Researcher
Invited?: Yes, Competitive?: Yes

45. (2021). Gut microbiome to predict cancer immunotherapy response/toxicity and improve treatment efficacy. IV International Workshop on Genomic Testing in Cancer: Facing a new era in personalised medicine, pampelona, Spain
Main Audience: Researcher
Invited?: Yes, Competitive?: Yes

46. (2021). Gut microbiome to predict cancer immunotherapy response and toxicity and improve treatment efficacy. Cours UIT session Microbiome - CRCHUM, Canada
Main Audience: Researcher
Invited?: Yes, Competitive?: Yes

47. (2021). Retour sur le cancer du poumon malgré le Covid. Présentation pour les oncologues et pharmaciens de l'hôpital de Rimouski, Canada
Main Audience: Researcher
Invited?: Yes, Competitive?: Yes

48. (2021). La prise en charge des toxicités sévères des immunothérapies.Réunion scientifique du département d'oncologie - Hôpital Legardeur, Canada
Main Audience: Researcher
Invited?: Yes, Competitive?: Yes

49. (2021). Gut microbiome in the immunotherapy arena from biomarker to therapeutics. 2021 CHU Lausanne, Switzerland
Main Audience: Researcher
Invited?: Yes, Competitive?: Yes

50. (2021). Gut microbiome in the immunotherapy arena from biomarker to therapeutics. 2021 ESMO Congress, France
Main Audience: Researcher
Invited?: Yes, Keynote?: No, Competitive?: Yes

51. (2021). Le microbiome intestinal pour prédire la réponse et toxicité de l'immunothérapie contre le cancer et améliorer l'efficacité du traitement. Exploring by the seat of your pants, Exploration de l'écosystème interne avec le Dr Bertrand Routy, Canada
Main Audience: General Public
Invited?: Yes, Competitive?: Yes

52. (2020). A new polyphenol prebiotic isolated from Myrciaria dubia improves gut microbiota composition and increases anti-PD-1 efficacy in murine cancer models.AACR, United States of America
Main Audience: Researcher
Invited?: No, Keynote?: No, Competitive?: Yes

53. (2020). Gut microbiome from bench to bedside, the second paradigm shift in cancer immunology?. Annual immunology meeting of Western London University, London, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes, Competitive?: Yes

54. (2020). Linking the gut microbiome to cancer immunotherapy response. SITC, United States of America
Main Audience: Researcher
Invited?: Yes, Keynote?: No, Competitive?: Yes

55. (2020). The gut microbiome as a key regulator of systemic immune response in cancer and in HIV.CTN meeting., Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes, Competitive?: Yes

56. (2020). Le microbiome intestinal est-il important dans la prise en charge des patients sous immunothérapie en 2020?. AMHOQ, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: No, Competitive?: Yes

57. (2020). Linking the gut microbiome to cancer immunotherapy response. H2020 annual meeting, Turin, Italy
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes, Competitive?: Yes

58. (2019). Gut microbiome immune potentiating effects in cancer therapies.2nd International Conference of the JIRU MicroMeNu., Quebec, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes, Competitive?: Yes

59. (2019). Gut microbiota, can we improve the outcome of cancer immunotherapy?. Porto Cancer meeting, Porto, Portugal
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes, Competitive?: Yes

60. (2019). How gut microbiome influences efficacy of immunotherapy?. Canadian Society for Pharmaceutical Sciences symposium, Vancouver, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes, Competitive?: Yes

61. (2019). Modification of the gut microbiota with prebiotics to enhance Immune Checkpoint Inhibitors activity. CCRC2019, Ottawa, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes, Competitive?: Yes

62. (2019). Immune-Potentiating Impact of the Gut Microbiome on Kidney Cancer Immune Infiltrate: A Novel Predictor of Immune Checkpoint Inhibitors Response.The Kidney Cancer Research Network of Canada (KCRNC), Toronto, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes, Competitive?: Yes

63. (2019). How gut microbiome influences efficacy of immunotherapy?. 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID2019), Amsterdam, Netherlands
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes, Competitive?: Yes

Broadcast Interviews

2022/05/27	Une baie amazonienne est appelée en renfort pour combattre le cancer, La presse Cannadienne, La Presse Canadienne
2022/05/06	Routy et al. Science 2018, La Presse Canadienne, La Presse Canadienne
2021/10/26	L’importance du microbiome chez les patients atteints d’un cancer, Société du Cancer du Canada, Société du Cancer du Canada
2021/04/15	Rôle de l’immunothérapie, Moteur de recherche, Radio Canada
2021/04/09	Le rôle de la greffe fécale en oncologie, Émission Pénélope McQuade, Radio Canada
2021/03/25	La greffe fécale pour augmenter l’efficacité de l’immunothérapie en mélanome, TVA nouvelles, TVA
2021/02/17	Microbiome en oncologie, Émission Découverte, Radio Canada
2020/11/12	Le microbiome et l'oncologie, Radio Ville Marie, Radio Ville Marie

Text Interviews

2021/04/26	Comment cibler l’intestin pour guérir le cancer de la peau, Journal de Montréal

Publications

Journal Articles

1. Yolchuyeva S, Ebrahimpour L, Tonneau M, Lamaze F, Orain M, Coulombe F, Malo J, Belkaid W, Routy B, Joubert P, Manem VS. (2024). Multi-institutional prognostic modeling of survival outcomes in NSCLC patients treated with first-line immunotherapy using radiomics. J Transl Med. 10(22): 42.
Published,
Refereed?: Yes

2. Routy B*, Jackson T, Mählmann L, Baumgartner CK, Blaser M, Byrd A, Corvaia N, Couts K, Davar D, Derosa L, Hang HC, Hospers G, Isaksen M, Kroemer G, Malard F, McCoy KD, Meisel M, Pal S, Ronai Z, Segal E, Sepich-Poore GD, Shaikh F, Sweis RF, Trinchieri G, van den Brink M, Weersma RK, Whiteson K, Zhao L, McQuade J, Zarour H, Zitvogel L. (2024). Melanoma and microbiota:Current understanding and future directions. Cancer Cell.42(1): 16-34.
Published,
Refereed?: Yes

3. Dia AK, Ebrahimpour L, Yolchuyeva S, Tonneau M, Lamaze FC, Orain M, Coulombe F, Malo J, Belkaid W, Routy B, Joubert P, Després P, Manem VSK. (2024). The Cross-Scale Association between Pathomics and Radiomics Features in Immunotherapy-Treated NSCLC Patients: A Preliminary Study.Cancers (Basel).16(2): 348.
Published,
Refereed?: Yes

4. Hes C, Desilets A, Tonneau M, El Ouarzadi O, De Figueiredo Sousa M, Bahig H, Filion É, Nguyen-Tan PF, Christopoulos A, Benlaïfaoui M, Derosa L, Alves Costa Silva C, Ponce M, Malo J, Belkad W, Charpentier D, Aubin F, Hamilou Z, Jamal R, Messaoudene M, Soulières D, Routy B*. (2024). Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma.Oral Oncol.148: 106623.
Published,
Refereed?: Yes

5. Alves Costa Silva C, Piccinno G, Suissa D, Bourgin M, Schreibelt G, Durand S, Birebent R, Fidelle M, Sow C, Aprahamian F, Manghi P, Puňcochář M, Asnicar F, Pinto F, Armanini F, Terrisse S, Routy B, Drubay D, Eggermont AMM, Kroemer G, Segata N, Zitvogel L, Derosa L, Bol KF, de Vries IJM. (2024). Influence of microbiota-associated metabolic reprogramming on clinical outcome inpatients with melanoma from the randomized adjuvant dendritic cell-basedMIND-DC trial.Nat Commun. 15(1): 1633.
Published,
Refereed?: Yes

6. Bredon M, Danne C, Pham HP, Ruffié P, Bessede A, Rolhion N, Creusot L, Brot L, Alonso I, Langella P, Derosa L, Cortot AB, Routy B, Zitvogel L, Segata N, Sokol H. (2024). Faecalibaterium prausnitzii strainEXL01 boosts efficacy of immune checkpoint inhibitors.Oncoimmunology. 1;13(1): 2374954.
Published,

7. Elkrief A, Méndez-Salazar EO, Maillou J, Vanderbilt CM, Gogia P, Desilets A, Messaoudene M, Kelly D, Ladanyi M, Hellmann MD, Zitvogel L, Rudin CM, Routy B, Derosa L, Schoenfeld AJ. (2024). Antibiotics are associated with worse outcomes in lungcancer patients treated with chemotherapy and immunotherapy.NPJ Precis Oncol. 16;8(1): 1.
Published,

8. Vahidian F, Lamaze FC, Bouffard C, Coulombe F, Gagné A, Blais F, Tonneau M, Orain M, Routy B, Manem VSK, Joubert P. (2024). CXCL13Positive Cells Localization Predict Response to Anti-PD-1/PD-L1 in PulmonaryNon-Small Cell Carcinoma.Cancers (Basel).16(4): 708.
Published,
Refereed?: Yes

9. Derosa L, Iebba V, Silva CAC, Piccinno G, Wu G, Lordello L, Routy B, Zhao N, Thelemaque C, Birebent R, Marmorino F, Fidelle M, Messaoudene M, Thomas AM, Zalcman G, Friard S, Mazieres J, Audigier-Valette C, Sibilot DM, Goldwasser F, Scherpereel A, Pegliasco H, Ghiringhelli F, Bouchard N, Sow C, Darik I, Zoppi S, Ly P, Reni A, Daillère R, Deutsch E, Lee KA, Bolte LA, Björk JR, Weersma RK, Barlesi F, Padilha L, Finzel A, Isaksen ML, Escudier B, Albiges L, Planchard D, André F, Cremolini C, Martinez S, Besse B, Zhao L, Segata N, Wojcik J, Kroemer G, Zitvogel L. (2024). Custom scoring based on ecological topology of gutmicrobiota associated with cancer immunotherapy outcome. Cell. 20;187(13): 3373-3389.
Published,

10. Hajjar R, Gonzalez E, Fragoso G, Oliero M, Alaoui AA, Calvé A, Vennin Rendos H, Djediai S, Cuisiniere T, Laplante P, Gerkins C, Ajayi AS, Diop K, Taleb N, Thérien S, Schampaert F, Alratrout H, Dagbert F, Loungnarath R, Sebajang H, Schwenter F, Wassef R, Ratelle R, Debroux E, Cailhier JF, Routy B, Annabi B, Brereton NJB, Richard C, Santos MM. (2023). Gut microbiota influence anastomotic healing in colorectal cancer surgery through modulation of mucosal proinflammatory cytokines.Gut. 72(6): 1143-1154.
Published,
Refereed?: Yes

11. Proulx-Rocray F, Routy B, Nassabein R, Belkaid W, Tran-Thanh D, Malo J, Tonneau M, Ouarzadi OE, Florescu M, Tehfe M, Blais N. (2023). The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.Cancer Treat Res Commun.37: 100767.
Published,
Refereed?: Yes

12. Duttagupta S, Hakozaki T, Routy B, Messaoudene M. (2023). The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer.Curr Oncol.30(11): 9406-9427.
Published,
Refereed?: Yes

13. Yolchuyeva S, Giacomazzi E, Tonneau M, Lamaze F, Orain M, Coulombe F, Malo J, Belkaid W, Routy B, Joubert P, Manem VSK. (2023). Radiomics approaches to predict PD-L1 and PFS in advanced non-small cell lung patients treated with immunotherapy: a multi-institutional study. Sci Rep. 13(1): 11065.
Published,
Refereed?: Yes

14. Yolchuyeva S, Giacomazzi E, Tonneau M, Lamaze F, Orain M, Coulombe F, Malo J, Belkaid W, Routy B, Joubert P, Manem VSK. (2023). Imaging-Based Biomarkers Predict Programmed Death-Ligand 1 and Survival Outcomes in Advanced NSCLC Treated With Nivolumab and Pembrolizumab: A Multi-Institutional Study.JTO Clin Res Rep. 4(12): 100602.
Published,
Refereed?: Yes

15. Yolchuyeva S, Giacomazzi E, Tonneau M, Ebrahimpour L, Lamaze FC, Orain M, Coulombe F, Malo J, Belkaid W, Routy B, Joubert P, Manem VSK. (2023). A Radiomics-Clinical Model Predicts Overall Survival of Non-Small Cell Lung Cancer Patients Treated with Immunotherapy: A Multicenter Study.Cancers (Basel). 15(15): 3829.
Published,
Refereed?: Yes

16. Routy B, Lenehan JG, Miller WH Jr, Jamal R, Messaoudene M, Daisley BA, Hes C, Al KF, Martinez-Gili L, Puňcochář M, Ernst S, Logan D, Belanger K, Esfahani K, Richard C, Ninkov M, Piccinno G, Armanini F, Pinto F, Krishnamoorthy M, Figueredo R, Thebault P, Takis P, Magrill J, Ramsay L, Derosa L, Marchesi JR, Parvathy SN, Elkrief A, Watson IR, Lapointe R, Segata N, Haeryfar SMM, Mullish BH, Silverman MS, Burton JP, Maleki Vareki S. (2023). Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nature Medicine. 29(8): 2121-2132..
First Listed Author
Published,
Refereed?: Yes

17. Bakouny Z, Labaki C, Grover P, Awosika J, Gulati S, Hsu CY, Alimohamed SI, Bashir B, Berg S, Bilen MA, Bowles D, Castellano C, Desai A, Elkrief A, Eton OE, Fecher LA, Flora D, Galsky MD, Gatti-Mays ME, Gesenhues A, Glover MJ, Gopalakrishnan D, Gupta S, Halfdanarson TR, Hayes-Lattin B, Hendawi M, Hsu E, Hwang C, Jandarov R, Jani C, Johnson DB, Joshi M, Khan H, Khan SA, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Matar S, McKay RR, Mishra S, Moria FA, Nizam A, Nock NL, Nonato TK, Panasci J, Pomerantz L, Portuguese AJ, Provenzano D, Puc M, Rao YJ, Rhodes TD, Riely GJ, Ripp JJ, Rivera AV, Ruiz-Garcia E, Schmidt AL, Schoenfeld AJ, Schwartz GK, Shah SA, Shaya J, Subbiah S, Tachiki LM, Tucker MD, Valdez-Reyes M, Weissmann LB, Wotman MT, Wulff-Burchfield EM, Xie Z, Yang YJ, Thompson MA, Shah DP, Warner JL, Shyr Y, Choueiri TK, Wise-Draper TM; COVID-19 and Cancer Consortium. (2023). Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19. JAMA oncol.9(1): 128-134.
Published,
Refereed?: Yes

18. Gulati S, Hsu CY, Shah S, Shah PK, Zon R, Alsamarai S, Awosika J, El-Bakouny Z, Bashir B, Beeghly A, Berg S, de-la-Rosa-Martinez D, Doroshow DB, Egan PC, Fein J, Flora DB, Friese CR, Fromowitz A, Griffiths EA, Hwang C, Jani C, Joshi M, Khan H, Klein EJ, Heater NK, Koshkin VS, Kwon DH, Labaki C, Latif T, McKay RR, Nagaraj G, Nakasone ES, Nonato T, Polimera HV, Puc M, Razavi P, Ruiz-Garcia E, Saliby RM, Shastri A, Singh SRK, Tagalakis V, Vilar-Compte D, Weissmann LB, Wilkins CR, Wise-Draper TM, Wotman MT, Yoon JJ, Mishra S, Grivas P, Shyr Y, Warner JL, Connors JM, Shah DP, Rosovsky RP; COVID-19 and Cancer Consortium. (2023). Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19.JAMA Oncol.17(23): 2934.
Published,
Refereed?: Yes

19. Wong P, Masucci L, Florescu M, Plourde ME, Panet-Raymond V, Pavic M, Owen S, Masson-Coté L, Ménard C, Routy B, Tehfe M, Nelson K, Guilbert F, Boucher O, Keshavarzi S, Blais N, Roberge D. (2023). Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases. Neuro-oncology advances. 5(1): vdad018.
Co-Author
Published,
Refereed?: Yes

20. Tonneau M, Richard C, Routy B, Campeau MP, Vu T, Filion E, Roberge D, Mathieu D, Doucet R, Beliveau-Nadeau D, Bahig H. (2023). A Competing Risk Analysis of the Patterns and Risk Factors of Recurrence in Early-Stage Non-Small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy. Radiotherapy and oncology. 185: 109697.
Co-Author
Published,
Refereed?: Yes

21. Jamal R, Messaoudene M, de Figuieredo M, Routy B. (2023). Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology. Seminar in immunology. 67: 101754.
Last Author
Published,
Refereed?: Yes

22. Dufour C, Richard C, Pardons M, Massanella M, Ackaoui A, Murrell B, Routy B, Thomas R, Routy JP, Fromentin R, Chomont N. (2023). Phenotypic characterization of single CD4+ T cells harboring genetically intact and inducible HIV genomes. Nat Commun. 14(1): 1115.
Published,
Refereed?: Yes

23. Thomas AM, Fidelle M, Routy B, Kroemer G, Wargo JA, Segata N, Zitvogel L. (2023). Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy. Nat Rev Clin Oncol. 20(9): 583-603..
In Press,
Refereed?: Yes

24. Benlaïfaoui M, Richard C, Diop A, Naimi S, Belkaid W, Bernet E, Veyrier F, Elkrief A, Bobay LM, Routy B, Diop K. (2023). Tractidigestivibacter montrealensis sp. nov., a newmember of human gut microbiota isolated from a healthy volunteer.FEMS Microbiol Lett.17: 370.
Published,
Refereed?: Yes

25. Ertl C, Ruf T, Mentzer D, Kong M, Kramer R, Bergwelt-Baildon MV, Subklewe M, Tomsitz D, Ascierto PA, Dummer R, Gogas H, Lebbé C, Long GV, McArthur G, Neilan TG, Ribas A, Robert C, Schadendorf D, Zimmer L, Eigentler T, Grabbe S, Forschner A, Kähler KC, Milani V, Pföhler C, Hassel J, Gutzmer R, Loquai C, Routy B, Furness AJS, Blank C, Wolchok JD, French LE, Hauschild A, Heinzerling L. (2023). The side effect registryimmuno-oncology (SERIO) - A tool for systematic analysis ofimmunotherapy-induced side effects.Eur J Cancer.199: 113505.
Published,
Refereed?: Yes

26. Yolchuyeva S, Giacomazzi E, Tonneau M, Ebrahimpour L, Lamaze FC, Orain M, Coulombe F, Malo J, Belkaid W, Routy B, Joubert P, Manem VSK. (2023). A Radiomics-Clinical Model Predicts Overall Survival of Non-Small Cell Lung Cancer Patients Treated with Immunotherapy: A Multicenter Study.Cancers (Basel). 15(15): 3829.
Published,
Refereed?: Yes

27. Diop K, Pidgeon R, Diop A, Benlaïfaoui M, Belkaid W, Malo J, Bernet E, Veyrier F, Jacq M, Brun Y, Elkrief A, Castagner B, Routy B, Richard C. (2023). Characterization and description of Gabonibacter chumensis sp. nov., isolated from feces of a patient with non-small cell lung cancer treated with immunotherapy. Arch Microbiol.205(10): 338.
Published,
Refereed?: Yes

28. Tonneau M, Phan K, Manem VSK, Low-Kam C, Dutil F, Kazandjian S, Vanderweyen D, Panasci J, Malo J, Coulombe F, Gagné A, Elkrief A, Belkaïd W, Di Jorio L, Orain M, Bouchard N, Muanza T, Rybicki FJ, Kafi K, Huntsman D, Joubert P, Chandelier F, Routy B. (2023). Generalization optimizing machine learning to improve CT scan radiomics and assess immune checkpoint inhibitors' response in non-small cell lung cancer: a multicenter cohort study.Front Oncol. 20(13): 1196414.
Published,
Refereed?: Yes

29. Léger MA, Routy B, Juneau D. (2022). FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients.Semin Nucl Med. 0(0): 0.
Co-Author
Published,
Refereed?: Yes

30. Terrisse S, Goubet AG, Ueda K, Thomas AM, Quiniou V, Thelemaque C, Dunsmore G, Clave E, Gamat-Huber M, Yonekura S, Ferrere G, Rauber C, Pham HP, Fahrner JE, Pizzato E, Ly P, Fidelle M, Mazzenga M, Costa Silva CA, Armanini F, Pinto F, Asnicar F, Daillère R, Derosa L, Richard C, Blanchard P, Routy B, Culine S, Opolon P, Silvin A, Ginhoux F, Toubert A, Segata N, McNeel DG, Fizazi K, Kroemer G, Zitvogel L. (2022). Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. J Immunother cancer. 10(3): 0.
Co-Author
Published,
Refereed?: Yes

31. Routy B*, Richard C, Benlaïfaoui M, Grandjean Lapierre S, Armstrong N, Al-Saleh A, Boko M, Jacq M, Watson I, Mihalcioiu C, Elkrief A, Tidjani Alou M, Messaoudene M, Diop K. (2022). Characterization of Alistipes montrealensis sp. nov., isolated from human feces of a patient with metastaticmelanoma treated with immune checkpoint inhibitors. Microbiology Research journal. 0: 0.
First Listed Author
Published,
Refereed?: Yes

32. Limagne E, Nuttin L, Thibaudin M, Jacquin E, Aucagne R, Bon M, Revy S, Barnestein R, Ballot E, Truntzer C, Derangère V, Fumet JD, Latour C, Rébé C, Bellaye PS, Kaderbhaï CG, Spill A, Collin B, Callanan MB, Lagrange A, Favier L, Coudert B, Arnould L, Ladoire S, Routy B, Joubert P, Ghiringhelli F. (2022). MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells. Cancer Cell. 0: 0.
Co-Author
Published,
Refereed?: Yes

33. Isnard S, Fombuena B, Ouyang J, Royston L, Lin J, Bu S, Sheehan N, Lakatos PL, Bessissow T, Chomont N, Klein M, Lebouché B, Costiniuk CT, Routy B, Marette A, Routy JP; Camu Camu Study Group. (2022). Camu Camu effects on microbial translocation and systemic immune activation in ART-treated people living with HIV: protocol ofthe single-arm non-randomised Camu Camu prebiotic pilot study (CIHR/CTN PT032). BMJ Open. 0: 0.
Co-Author
Published,
Refereed?: Yes

34. Tonneau M, Nolin-Lapalme A, Kazandjian S, Auclin E, Panasci J, Benlaifaoui M, Ponce M, Al-Saleh A, Belkaid W, Naimi S, Catalin Mihalcioiu C, Watson I, Miller W, Hudson M, Wong M.K, Pezo R.C Turcotte S, Bélanger K, Jamal R, Oster P, Velin D, Richard C, Messaoudene M, Elkrief A, Routy B*. (2022). Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors.Oncoimmunology. 0(0): 0.
Last Author
Published,
Refereed?: Yes, Open Access?: No

35. Derosa L*, Routy B*, Thomas AM, Iebba V, Zalcman G, Friard S, Mazieres J, Audigier-Valette C, Moro-Sibilot D, Goldwasser F, Silva CAC, Terrisse S, Bonvalet M, Scherpereel A, Pegliasco H, Richard C, Ghiringhelli F, Elkrief A, Desilets A, Blanc-Durand F, Cumbo F, Blanco A, Boidot R, Chevrier S, Daillère R, Kroemer G, Alla L, Pons N, Le Chatelier E, Galleron N, Roume H, Dubuisson A, Bouchard N, Messaoudene M, Drubay D, Deutsch E, Barlesi F, Planchard D, Segata N, Martinez S, Zitvogel L, Soria JC, Besse B. (2022). Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-celllung cancer. Nat Med. 28(2): 315-324..
First Listed Author
Published,
Refereed?: Yes

36. Bahig H, Tonneau M, Blais N, Wong P, Filion E, Campeau M-P, Vu T, Al-Saleh A, Tehfé M, Florescu M, Roberge D, Masucci L, Richard C, Menard C, Routy B*. (2022). Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy inNon-Small Cell Lung Cancer: A Registry-based Phase II Randomized Trial(SUPPRESS-NSCLC). Clin Transl Radiat Oncol. 0: 0.
Last Author
In Press,
Refereed?: Yes

37. Hakozaki T, Nolin-Lapalme A, Kogawa M, Okuma Y, Nakamura S, Mo-reai-Amaru D, Tamura T, Hosomi Y, Takeyama H, Richard C, Hosokawa M, Routy B*. (2022). Cancer Cachexia amongPatients with Advanced Non-small-Cell Lung Cancer on Immunotherapy: AnObservational Study with Exploratory Gut Microbiota Analysis. Cancers. 14(21): 5405..
Published,
Refereed?: Yes

38. Hajjar R, Gonzalez E, Fragoso G, Oliero M, Alaoui AA, Calvé A, Vennin Rendos H, Djediai S, Cuisiniere T, Laplante P, Gerkins C, Ajayi A, Diop K, Taleb N, Thérien S, Schampaert F, Alratrout H, Dagbert F, Loungnarath R, Sebajang H, Schwenter F, Wassef R, Ratelle R, Debroux E, Cailhier JF, Routy B, Annabi B, Brereton N, Carole Richard C, Santos M. (2022). Gut microbiota influence anastomotic healing incolorectal cancer surgery through modulation of mucosal pro-inflammatorycytokines. Gut.72(6): 1143-1154.
Published,
Refereed?: Yes

39. Lecuelle J, Favier L, Fraisse C, Lagrange A, Kaderbhai C, Boidot R, Chevrier S, Joubert P, Routy B, Truntzer C, Ghiringhelli F. (2022). MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapyin non-small cell lung cancer. J Immunother Cancer. 0: 0.
Co-Author
Published,
Refereed?: Yes

40. Messaoudene M, Pidgeon R, Richard C, Ponce M, Diop K, Benlaifaoui M, Nolin-Lapalme A, Cauchois F, Malo J, Belkaid W, Isnard S, Fradet Y, Dridi L, Velin D, Oster P, Raoult D, Ghiringhelli F, Boidot R, Chevrier S, T Kysela D, V Brun Y, Liana Falcone E, Pilon G, Plaza Oñate F, Gitton-Quent O, Le Chatelier E, Durand S, Kroemer G, Elkrief A, Marette A, Castagner B, Routy B*. (2022). A natural polyphenol exerts antitumor activity and circumvents anti-PD-1resistance through effects on the gut microbiota. Cancer Discov. 0: 0.
Last Author
Published,
Refereed?: Yes

41. Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen W-S, Derosa L, Khan MAW, Cogdill AP, White MG, Wong MC, Ferrere G, Fluckiger A, Roberti MP, Opolon P, Alou MT, Yonekura S, Roh W, Spencer S, Arora R, Morad G, Lastrapes M, Baruch EN, Little L, Gumbs C, Cooper ZA, Prieto PA, Wani K, Lazar AJ, Tetzlaff MT, Hudgens CW, Callahan MK, Adamow M, Mihalcioiu C, Elkrief A, Pezo RC, Haydu LE, Simon JM, Tawbi HA, McQuade J, Hwu P, Hwu W-J, Amaria RN, Burton EM, Woodman SE, Watowich S, Diab A, Patel SP, Glitza IC, Wong MK, Zhao L, Zhang J, Ajami NJ, Petrosino J, Jenq RR, Davies MA, Gershenwald JE, Futreal PA, Sharma P, Allison JP, Routy B, Zitvogel L, Wargo JA. (2021). Gut microbiota signatures are associated with toxicityto combined CTLA-4 and PD-1 blockade. Nat Med. 0: 0.
Co-Author
Published,
Refereed?: Yes

42. Yonekura S, Terrisse S, Alves Costa Silva C, Lafarge A, Iebba V, Ferrere G, Goubet AG, Fahrner JE, Lahmar I, Ueda K, Mansouri G, Pizzato E, Ly P, Mazzenga M, Thelemaque C, Fidelle M, Jaulin F, Cartry J, Deloger M, Aglave M, Droin N, Opolon P, Puget A, Mann F, Neunlist M, Bessard A, Aymeric L, Matysiak-Budnik T, Bosq J, Hofman P, Duong CPM, Ugolini S, Quiniou V, Berrard S, Ryffel B, Kepp O, Kroemer G, Routy B, Lordello L, Bani MA, Segata N, Yousef Yengej F, Clevers H, Scoazec JY, Pasolli E, Derosa L, Zitvogel L. (2021). Cancer induces a stress ileopathy depending on B-adrenergic receptors and promotingdysbiosis that contribute to carcinogenesis. Cancer Discov. 0: 0.
Co-Author
Published,
Refereed?: Yes

43. Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin A-L, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, Pietrantonio F, Routy B, André F, Pasolli E, Delaloge S, Zitvogel L. (2021). Intestinal microbiota influences clinical outcome andside effects of early breast cancertreatment. Cell Death Differ. 0: 0.
Co-Author
Published,
Refereed?: Yes

44. Shaikh FY, White JR, Gills JJ, Hakozaki T, Richard C, Routy B, Okuma Y, Usyk M, Pandey A, Weber JS, Ahn J, Lipson EJ, Naidoo J, Pardoll DM, Sears CL. (2021). A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers ofNonresponse to Immune CheckpointInhibitors. Clin Cancer Res. 0: 0.
Co-Author
Published,
Refereed?: Yes

45. Ahmed DS, Isnard S, Lin J, Routy B, Routy J-P. (2021). GDF15/GFRAL Pathway as a Metabolic Signature for Cachexia in Patients with Cancer. J Cancer. 0: 0.
Co-Author
Published,
Refereed?: Yes

46. Cvetkovic L, Régis C, Richard C, Derosa L, Leblond A, Malo J, Messaoudene M, Desilets A, Belkaid W, Elkrief A, Routy B*, Juneau D. (2021). Physiologic colonic uptake of 18F-FDG on PET/CT isassociated with clinical response and gut microbiome composition in patientswith advanced non-small cell lung cancer treated with immune checkpointinhibitors. Eur J Nucl Med Mol Imaging. 0: 0.
Co-Author
Published,
Refereed?: Yes

47. Niogret J, Berger H, Rebe C, Mary R, Ballot E, Truntzer C, Thibaudin M, Derangère V, Hibos C, Hampe L, Rageot D, Accogli T, Joubert P, Routy B, Harker J, Vegran F, Ghiringhelli F, Chalmin F. (2021). Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy. J Immunother Cancer. 0: 0.
Co-Author
Published,
Refereed?: Yes

48. Desilets A, Elkrief A, Routy B*. (2021). The Link Between the Gut Microbiome and Response toImmune Checkpoint Inhibitors in RenalCell Carcinoma. Eur Urol. 0: 0.
Last Author
Published,
Refereed?: Yes

49. Sannier G, Dubé M, Dufour C, Richard C, Brassard N, Delgado GG, Pagliuzza A, Baxter AE, Niessl J, Brunet-Ratnasingham E, Charlebois R, Routy B, Routy JP, Fromentin R, Chomont N, Kaufmann DE. (2021). Combined single-cell transcriptional, translational, andgenomic profiling reveals HIV-1 reservoir diversity. Cell Rep. 0: 0.
Co-Author
Published,
Refereed?: Yes

50. Desilets A, Blanc-Durand F, Lau S, Hakozaki T, Kitadai R, Malo J, Belkaid W, Richard C, Messaoudene M, Cvetkovic L, Kazandjian S, Tehfe M, Florescu M, Jao K, Daaboul N, Owen S, Shieh B, Agulnik J, Cohen V, Charbonneau C, Marcoux N, Blais N, Leighl NB, Bradbury PA, Liu G, Shepherd FA, Bahig H, Routy B*, Sacher A, Elkrief A. (2021). Durvalumab therapy following chemoradiation compared with a historical cohort treated withchemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study. Eur J Cancer. 0: 0.
Co-Author
Published,
Refereed?: Yes

51. Blanc-Durand F, Florescu M, Tehfe M, Routy B, Alameddine R, Tran-Thanh D, Blais N. (2021). Improvement of EGFR Testing over the Last Decade andImpact of Delaying TKI Initiation. Curr Oncol. 0: 0.
Co-Author
Published,
Refereed?: Yes

52. Elkrief A, Routy B*. (2021). First clinical proof-of-concept that FMT can overcomeresistance to ICIs. Nat Rev Clin Oncol. 0: 0.
Last Author
Published,
Refereed?: Yes

53. Dubuisson A, Fahrner J-E, Goubet A-G, Terrisse S, Voisin N, Bayard C, Lofek S, Drubay D, Bredel D, Mouraud S, Susini S, Cogdill A, Rebuffet L, Ballot E, Jacquelot N, Thomas de Montpreville V, Casiraghi O, Radulescu C, Ferlicot S, Figueroa DJ, Yadavilli S, Waight JD, Ballas M, Hoos A, Condamine T, Parier B, Gaudillat C, Routy B, Ghiringhelli F, Derosa L, Breuskin I, Rouanne M, André F, Lebacle C, Baumert H, Wislez M, Fadel E, Cremer I, Albiges L, Geoerger B, Scoazec J-Y, Loriot Y, Kroemer G, Marabelle A, Bonvalet M, Zitvogel L. (2021). Immunodynamics of explanted human tumors for immuno-oncology. EMBO Mol Med. 0: 0.
Co-Author
Published,
Refereed?: Yes

54. Isnard S, Fombuena B, Sadouni M, Lin J, Richard C, Routy B, Ouyang J, Ramendra R, Peng X, Zhang Y, Finkelman M, Tremblay-Sher D, Tremblay C, Chartrand-Lefebvre C, Durand M, Routy J-P. (2021). Circulating β-d-Glucan as a Marker of Subclinical Coronary Plaque in Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus. Open Forum Infect Dis. 0: 0.
Co-Author
Published,
Refereed?: Yes

55. Oster P, Vaillant L, Riva E, McMillan B, Begka C, Truntzer C, Richard C, Leblond MM, Messaoudene M, Machremi E, Limagne E, Ghiringhelli F, Routy B, Verdeil G, Velin D. (2021). Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies. Gut. 0: 0.
Co-Author
Published,
Refereed?: Yes

56. Tonneau M, Elkrief A, Pasquier D, Paz Del Socorro T, Chamaillard M, Bahig H, Routy B*. (2021). The role of the gut microbiome on radiation therapy efficacy and gastrointestinal complications: A systematic review. Radiother Oncol. 0: 0.
Last Author
Published,
Refereed?: Yes

57. Deschênes-Simard X, Richard C, Galland L, Blais F, Desilets A, Malo J, Cvetkovic L, Belkaid W, Elkrief A, Gagné A, Hamel M-A, Orain M, Joubert P, Ghiringhelli F, Routy B, Blais N. (2021). Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small celllung cancer: A retrospective multicentric cohortstudy. Thromb Res. 0: 0.
Co-Author
Published,
Refereed?: Yes

58. Derosa L, Routy B, Desilets A, Daillère R, Terrisse S, Kroemer G, Zitvogel L. (2021). Microbiota-Centered Interventions:The Next Breakthrough in Immuno-Oncology?. Cancer Discov. 0: 0.
Co-Author
Published,
Refereed?: Yes

59. Gauvin C, Krishnan V, Kaci I, Tran-Thanh D, Bédard K, Albadine R, Leduc C, Gaboury L, Blais N, Tehfe M, Routy B, Florescu M. (2021). Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC. Curr Oncol. 0: 0.
Co-Author
Published,
Refereed?: Yes

60. Goubet A-G, Dubuisson A, Geraud A, Danlos F-X, Terrisse S, Silva CAC, Drubay D, Touri L, Picard M, Mazzenga M, Silvin A, Dunsmore G, Haddad Y, Pizzato E, Ly P, Flament C, Melenotte C, Solary E, Fontenay M, Garcia G, Balleyguier C, Lassau N, Maeurer M, Grajeda-Iglesias C, Nirmalathasan N, Aprahamian F, Durand S, Kepp O, Ferrere G, Thelemaque C, Lahmar I, Fahrner J-E, Meziani L, Ahmed-Belkacem A, Saïdani N, La Scola B, Raoult D, Gentile S, Cortaredona S, Ippolito G, Lelouvier B, Roulet A, Andre F, Barlesi F, Soria J-C, Pradon C, Gallois E, Pommeret F, Colomba E, Ginhoux F, Kazandjian S, Elkrief A, Routy B, Miyara M, Gorochov G, Deutsch E, Albiges L, Stoclin A, Gachot B, Florin A, Merad M, Scotte F, Assaad S, Kroemer G, Blay J-Y, Marabelle A, Griscelli F, Zitvogel L, Derosa L. (2021). Prolonged SARS-CoV-2 RNA virus shedding and lymphopeniaare hallmarks of COVID-19 in cancer patientswith poor prognosis. Cell Death Differ. 0: 0.
Co-Author
Published,
Refereed?: Yes

61. Picard M, Yonekura S, Slowicka K, Petta I, Rauber C, Routy B, Richard C, Iebba V, Tidjani Alou M, Becharef S, Ly P, Pizzato E, Lehmann CHK, Amon L, Klein C, Opolon P, Gomperts Boneca I, Scoazec J-Y, Hollebecque A, Malka D, Ghiringhelli F, Dudziak D, Berx G, Vereecke L, van Loo G, Kroemer G, Zitvogel L, Roberti MP. (2021). Ileal immune tonus is a prognosis marker of proximalcolon cancer in mice and patients. Cell Death Differ. 0: 0.
Co-Author
Published,
Refereed?: Yes

62. Isnard S , Lin J , Fombuena B , Ouyang J , Varin TV , Richard C , Marette A , Ramendra R , Planas D , Raymond Marchand L , Messaoudene M , Van der Ley CP , Kema IP , Sohail Ahmed D , Zhang Y , Finkelman M , Routy B , Angel J , Ancuta P , Routy JP. (2020). Repurposing Metformin in Nondiabetic People With HIV: Influence on Weight and Gut Microbiota.Open forum infectious diseases. 7(9): ofaa338.
Co-Author
Published,
Refereed?: Yes

63. COVID-19 and Cancer Consortium. Electronic address: jeremy.warner@vumc.org , COVID-19 and Cancer Consortium. (2020). A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance.Cancer cell. 0: 0.
Co-Author
Published,
Refereed?: Yes

64. Routy B* , Derosa L , Zitvogel L , Kroemer G. (2020). COVID-19: a challenge for oncology services.Oncoimmunology. 9(1): 1760686.
First Listed Author
Published,
Refereed?: Yes

65. Wilson BE , Routy B , Nagrial A , Chin VT. (2020). The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies.Cancer immunology, immunotherapy : CII. 69(3): 343-354.
Co-Author
Published,
Refereed?: Yes

66. Medjebar S , Truntzer C , Perrichet A , Limagne E , Fumet JD , Richard C , Elkrief A , Routy B , Rébé C , Ghiringhelli F. (2020). Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers.Oncoimmunology. 9(1): 1836766.
Co-Author
Published,
Refereed?: Yes

67. Ballot E , Ladoire S , Routy B , Truntzer C , Ghiringhelli F. (2020). Tumor Infiltrating Lymphocytes Signature as a New Pan-Cancer Predictive Biomarker of Anti PD-1/PD-L1 Efficacy.Cancers. 12(9): 0.
Co-Author
Published,
Refereed?: Yes

68. Lepletier A , Madore J , O'Donnell JS , Johnston RL , Li XY , McDonald E , Ahern E , Kuchel A , Eastgate M , Pearson SA , Mallardo D , Ascierto PA , Massi D , Merelli B , Mandala M , Wilmott JS , Menzies AM , Leduc C , Stagg J , Routy B , Long GV , Scolyer RA , Bald T , Waddell N , Dougall WC , Teng MWL , Smyth MJ. (2020). Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research. 26(14): 3671-3681.
Co-Author
Published,
Refereed?: Yes

69. Hakozaki T , Richard C , Elkrief A , Hosomi Y , Benlaïfaoui M , Mimpen I , Terrisse S , Derosa L , Zitvogel L , Routy B , Okuma Y. (2020). The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer.Cancer immunology research. 8(10): 1243-1250.
Co-Author
Published,
Refereed?: Yes

70. Nassabein R , Routy B , Blais N , Ayoub JP , Tehfé M. (2020). Arterial thrombosis and coronavirus disease 2019 in a patient with cancer.European journal of cancer (Oxford, England : 1990). 134: 1-2.
Co-Author
Published,
Refereed?: Yes

71. Elkrief A , Richard C , Malo J , Cvetkovic L , Florescu M , Blais N , Tehfe M , Messaoudene M , Gagné A , Orain M , Medjebar S , Wan-Chow-Wah D , Joubert P , Labbé C , Ghiringhelli F , Routy B. (2020). Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer: Real-world data from multicentric cohorts in Canada and France.Journal of geriatric oncology. 11(5): 802-806.
Last Author
Published,
Refereed?: Yes

72. Esfahani K , Elkrief A , Calabrese C , Lapointe R , Hudson M , Routy B , Miller WH , Calabrese L. (2020). Moving towards personalized treatments of immune-related adverse events.Nature reviews. Clinical oncology. 17(8): 504-515.
Co-Author
Published,
Refereed?: Yes

73. Blanc-Durand F , Alameddine R , Iafrate AJ , Tran-Thanh D , Lo YC , Blais N , Routy B , Tehfé M , Leduc C , Romeo P , Stephenson P , Florescu M. (2020). Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion.The oncologist. 0: 0.
Co-Author
Published,
Refereed?: Yes

74. Elkrief A , Joubert P , Florescu M , Tehfe M , Blais N , Routy B*. (2020). Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020.Current oncology (Toronto, Ont.). 27(1): 52-60.
Last Author
Published,
Refereed?: Yes

75. Medjebar S, Truntzer C, Perrichet A, Limagne E, Fumet J-D, Richard C, Elkrief A, Routy B, Rébé C, Ghiringhelli F. (2020). Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers. Oncoimmunology. 9(1): 1836766.
Published,
Refereed?: Yes

76. Roberti MP , Yonekura S , Duong CPM , Picard M , Ferrere G , Tidjani Alou M , Rauber C , Iebba V , Lehmann CHK , Amon L , Dudziak D , Derosa L , Routy B , Flament C , Richard C , Daillère R , Fluckiger A , Van Seuningen I , Chamaillard M , Vincent A , Kourula S , Opolon P , Ly P , Pizzato E , Becharef S , Paillet J , Klein C , Marliot F , Pietrantonio F , Benoist S , Scoazec JY , Dartigues P , Hollebecque A , Malka D , Pagès F , Galon J , Gomperts Boneca I , Lepage P , Ryffel B , Raoult D , Eggermont A , Vanden Berghe T , Ghiringhelli F , Vandenabeele P , Kroemer G , Zitvogel L. (2020). Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer.Nature medicine. 26(6): 919-931.
Co-Author
Published,
Refereed?: Yes

77. Fluckiger A , Daillère R , Sassi M , Sixt BS , Liu P , Loos F , Richard C , Rabu C , Alou MT , Goubet AG , Lemaitre F , Ferrere G , Derosa L , Duong CPM , Messaoudene M , Gagné A , Joubert P , De Sordi L , Debarbieux L , Simon S , Scarlata CM , Ayyoub M , Palermo B , Facciolo F , Boidot R , Wheeler R , Boneca IG , Sztupinszki Z , Papp K , Csabai I , Pasolli E , Segata N , Lopez-Otin C , Szallasi Z , Andre F , Iebba V , Quiniou V , Klatzmann D , Boukhalil J , Khelaifia S , Raoult D , Albiges L , Escudier B , Eggermont A , Mami-Chouaib F , Nistico P , Ghiringhelli F , Routy B , Labarrière N , Cattoir V , Kroemer G , Zitvogel L. (2020). Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage.Science (New York, N.Y.). 369(6506): 936-942.
Co-Author
Published,
Refereed?: Yes

78. Elkrief A , Desilets A , Papneja N , Cvetkovic L , Groleau C , Lakehal YA , Shbat L , Richard C , Malo J , Belkaid W , Cook E , Doucet S , Tran TH , Jao K , Daaboul N , Bhang E , Loree JM , Miller WH , Vinh DC , Bouganim N , Batist G , Letendre C , Routy B*. (2020). High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study.European journal of cancer (Oxford, England : 1990). 139: 181-187.
Last Author
Published,
Refereed?: Yes

79. Desilets A , Elkrief A , Routy B*. (2020). The Link Between the Gut Microbiome and Response to Immune Checkpoint Inhibitors in Renal Cell Carcinoma.European urology. 0: 0.
Last Author
Published,
Refereed?: Yes

80. Ouyang J , Isnard S , Lin J , Fombuena B , Marette A , Routy B , Chen Y , Routy JP. (2020). Metformin effect on gut microbiota: insights for HIV-related inflammation.AIDS research and therapy. 17(1): 10.
Co-Author
Published,
Refereed?: Yes

81. Alves Costa Silva C , Facchinetti F , Routy B , Derosa L. (2020). New pathways in immune stimulation: targeting OX40.ESMO open. 5(1): 0.
Co-Author
Published,
Refereed?: Yes

82. Ouyang J , Lin J , Isnard S , Fombuena B , Peng X , Marette A , Routy B , Messaoudene M , Chen Y , Routy JP. (2020). The Bacterium Akkermansia muciniphila : A Sentinel for Gut Permeability and Its Relevance to HIV-Related Inflammation.Frontiers in immunology. 11: 645.
Co-Author
Published,
Refereed?: Yes

83. Derosa L , Routy B* , Fidelle M , Iebba V , Alla L , Pasolli E , Segata N , Desnoyer A , Pietrantonio F , Ferrere G , Fahrner JE , Le Chatellier E , Pons N , Galleron N , Roume H , Duong CPM , Mondragón L , Iribarren K , Bonvalet M , Terrisse S , Rauber C , Goubet AG , Daillère R , Lemaitre F , Reni A , Casu B , Alou MT , Alves Costa Silva C , Raoult D , Fizazi K , Escudier B , Kroemer G , Albiges L , Zitvogel L. (2020). Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.European urology. 78(2): 195-206.
First Listed Author
Published,
Refereed?: Yes

84. Cvetkovic L , Régis C , Richard C , Derosa L , Leblond A , Malo J , Messaoudene M , Desilets A , Belkaid W , Elkrief A , Routy B , Juneau D. (2020). F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.European journal of nuclear medicine and molecular imaging. 0: 0.
Co-Author
Published,
Refereed?: Yes

85. Daillère R , Routy B , Goubet AG , Cogdill A , Ferrere G , Alves-Costa Silva C , Fluckiger A , Ly P , Haddad Y , Pizzato E , Thelemaque C , Fidelle M , Mazzenga M , Roberti MP , Melenotte C , Liu P , Terrisse S , Kepp O , Kroemer G , Zitvogel L , Derosa L. (2020). Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors.Oncoimmunology. 9(1): 1794423.
Co-Author
Published,
Refereed?: Yes

86. Daillère R , Derosa L , Bonvalet M , Segata N , Routy B , Gariboldi M , Budinská E , De Vries IJM , Naccarati AG , Zitvogel V , Caldas C , Engstrand L , Loilbl S , Fieschi J , Heinzerling L , Kroemer G , Zitvogel L. (2020). Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy.Oncoimmunology. 9(1): 1774298.
Co-Author
Published,
Refereed?: Yes

87. Elkrief A , El Raichani L , Richard C , Messaoudene M , Belkaid W , Malo J , Belanger K , Miller W , Jamal R , Letarte N , Wong P , Routy B*. (2019). Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors.Oncoimmunology. 8(4): e1568812.
Last Author
Published,
Refereed?: Yes

88. Messaoudene M , Mourikis TP , Michels J , Fu Y , Bonvalet M , Lacroix-Trikki M , Routy B , Fluckiger A , Rusakiewicz S , Roberti MP , Cotteret S , Flament C , Poirier-Colame V , Jacquelot N , Ghiringhelli F , Caignard A , Eggermont AMM , Kroemer G , Marabelle A , Arnedos M , Vicier C , Dogan S , Jaulin F , Sammut SJ , Cope W , Caldas C , Delaloge S , McGranahan N , André F , Zitvogel L. (2019). T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants.Annals of oncology : official journal of the European Society for Medical Oncology. 30(6): 934-944.
Co-Author
Published,
Refereed?: Yes

89. Elkrief A , Derosa L , Kroemer G , Zitvogel L , Routy B*. (2019). The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?. Annals of oncology : official journal of the European Society for Medical Oncology. 30(10): 1572-1579.
Last Author
Published,
Refereed?: Yes

90. Elkrief A , Derosa L , Zitvogel L , Kroemer G , Routy B*. (2019). The intimate relationship between gut microbiota and cancer immunotherapy.Gut microbes. 10(3): 424-428.
Last Author
Published,
Refereed?: Yes

Intellectual Property

Patents

1. Biological marker of intestinal dysbiosis, useful for predicting the response of a cancer patient to an anti-PD1 drug. France. 2022/06/30.
Patent Status: Pending
Inventors: Laurence Zitvogel, Lisa Derosa, Bertrand Routy

2. Efficiency of Camu-Camu in the increase immune checkpoints inhibitors activity in cancer. Canada. G17004-00008-AD. 2019/02/01.
Patent Status: Pending

3. Gut microbial fingerprint based on metagenomics profiling of patients stools to predict clinical resistance/ response to anti-PD1/PD-L1/PD-L2 blockade in cancer. France. EP17305206. 2017/12/01.
Patent Status: Allowed
Year Issued: 2017
Inventors: Laurence Zitvogel, Bertrand Routy, Emmanuelle Lechatellier